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Abstract: Zusammenfassung Die chronische Niereninsuffizienz (CKD) stellt einen bedeutenden Risiko-
faktor für die Entstehung kardiovaskulärer Ereignisse dar. Bereits eine nur leichtgradig eingeschränkte
Nierenfunktion ist bereits mit einem erhöhten kardiovaskulären Risiko assoziiert. High- density Lipopro-
tein (HDL) von Gesunden weist neben seiner Rolle im reversen Cholesterintransport bedeutende an-
tiatherogene Eigenschaften auf. Allerdings zeigen aktuelle Studien, dass die vaskulären Effekte von HDL
sehr heterogen sein können. Ziel des Projektes war es, die vasoprotektiven Eigenschaften von HDL von
Patienten mit einer chronischen Niereninsuffizienz zu untersuchen. Im Gegensatz zu HDL von Gesun-
den (HDLHealthy) führte die Inkubation von humanen aortalen Endothelzellen (HAEC) mit HDL von
Nierenkranken (HDLCKD) zu einer dramatischen Hemmung der endothelialen Stickstoffmonoxid (NO)
Produktion. Dieser Effekt war bereits mit HDL von Patienten mit nur leichtgradig eingeschränkter
Nierenfunktion zu beobachten. Im Mausmodell führte eine Injektion von HDLCKD zu einem Blutdruck-
anstieg, während HDLHealthy den Blutdruck reduzierte. Ferner konnten wir zeigen, dass HDLCKD in
HAEC die Produktion von Superoxid-Radikalen stimuliert. Mittels Massenspektromie konnten wir die
Akkumulation von symmetrischem Dimethylarginin (SDMA) in HDLCKD aber nicht in HDLHealthy
nachweisen. Außerdem konnten wir zeigen, dass die Inkorporation von SDMA in den HDL (HDLS-
DMA) Partikel zur Veränderung der endothelialen Eigenschaften von HDL führt. HDLSDMA hemmte
die endotheliale NO-Produktion und förderte die Produktion von Superoxid-Radikalen. Weiter konnten
wir nachweisen, dass die Effekte von HDLCKD als auch HDLSDMA durch eine Aktivierung des Toll-
like Rezeptors-2 (TLR-2) auf der Oberfläche von Endothelzellen vermittelt werden. Im Gegensatz zu
klassischen TLR-2 Liganden, die via TLR-2 zusammen mit den Co-Rezeptoren TLR-1 und TLR-6 die
NF-￿B abhängige Cytokinproduktion stimulieren, konnten wir erstmalig aufzeigen, dass für die TLR-2-
abhängige Aktivierung von Endothelzellen durch HDLCKD und HDLSDMA diese Co-Rezeptoren nicht
notwendig sind. HDLCKD und HDLSDMA führen beiden über eine Aktivierung des endothelialen TLR-
2 zu einer direkten Hemmung der stimulatorischen Akt-abhängigen Phosphorylierung der endothelialen
NO Synthase (eNOS) sowie via Phosphorylierung von SAPK/JNK zu einer NADPH-Oxidase abhängi-
gen Produktion von Superoxid-Radikalen. Schließlich konnten wir nachweisen, dass die Reduktion der
endothelialen NO-Bioverfügbarkeit durch HDLCKD und HDLSDMA auch zu einer Aufhebung der anti-
inflammatorischen Eigenschaften von HDL und der positiven Eigenschaften des HDL auf die Reparatur
von Endothelläsionen führt. Zusammenfassend konnten wir erstmals zeigen, dass HDL von Nierenkranken
endothelialer Dysfunktion sowie einen Anstieg des Blutdrucks induziert. Wir konnten ferner nachweisen,
dass die Akkumulation von SDMA im HDL von Nierenkranken die Umkehr der physiologischen Eigen-
schaften des HDLs hin zu einem gefäßschädigenden Partikel induziert. Insgesamt zeigen diese Ergebnisse
einen neuen Zusammenhang zwischen endothelialer Dysfunktion, arterieller Hypertonie sowie dem ange-
borenen Immunsystem auf. Summary Chronic kidney disease (CKD) represents a potent cardiovascular
risk factor. Thereby, a slightly reduced renal function is already associated with an elevated risk for car-
diovascular events. Besides its role in the reverse cholesterol transport, high-density lipoprotein (HDL)
from healthy subjects exerts several important vascular effects. However, recent evidence suggests that
the vascular properties of HDL can be highly heterogeneous. The aim of the present project was to exam-
ine the vasoprotective effects of HDL from patients with CKD. In contrast to HDL from healthy subjects
(HDLHealthy), incubation of human aortic endothelial cells (HAEC) with HDL from patients with CKD
(HDLCKD) markedly inhibited endothelial nitric oxide (NO) production. Interestingly, this effect was
already present with HDL from patients with incipient CKD. In a mouse model, HDLCKD increased the
arterial blood pressure, whereas HDLHealthy reduced the arterial blood pressure. Moreover, we could
show that HDLCKD induced the production of superoxide radicals in HAEC. Using a mass-spectrometry
approach, we identified the accumulation of symmetric dimethylarginine (SDMA) in HDLCKD, but not
in HDLHealthy. Moreover, we could demonstrate that incorporation of SDMA into HDL (HDLSDMA)
inverts the vasoprotective properties of HDL. HDLSDMA inhibited endothelial NO production and stim-
ulated superoxide production in HAEC. Subsequently, we could reveal that the adverse vascular effects
of HDLHealthy as well as HDLSDMA are mediated by Toll-like receptor-2 (TLR-2) on the surface of
endothelial cells. In contrast to classical TLR-2 ligand, in which hetero-dimers of TLR-1/2 or TLR2/6
mediate NF-￿B-dependent cytokine secretion, we could show for the first time that TLR-2 dependent
endothelial activation by HDLCKD or HDLSDMA is co-receptor independent. Moreover, we found that
activation of endothelial TLR-2 by HDLCKD or HDLSDMA directly reduces the Akt-dependent stimula-
tory phosphorylation of endothelial NO synthase (eNOS) and stimulates the NADPH-oxidase dependent
endothelial superoxide production via phosphorylation of SAPK/JNK. Moreover, our results indicate
that the reduced endothelial NO bioavailability in response to HDLCKD or HDLSDMA suppresses the
anti-inflammatory properties of HDL as well as the effects of HDL on endothelial repair. In summary, we
could show for the first time that HDLCKD induces endothelial dysfunction and increases arterial blood
pressure. Moreover, we identified SDMA in the HDL fraction as the culprit transforming HDLCKD from
a vasoprotective into a noxious particle. Of note, these findings reveal a novel link between endothelial
dysfunction, hypertension and innate immunity.
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1 Zusammenfassung 
Die chronische Niereninsuffizienz (CKD) stellt einen bedeutenden Risikofaktor für die 
Entstehung kardiovaskulärer Ereignisse dar. Bereits eine nur leichtgradig eingeschränkte 
Nierenfunktion ist bereits mit einem erhöhten kardiovaskulären Risiko assoziiert. High-
density Lipoprotein (HDL) von Gesunden weist neben seiner Rolle im reversen 
Cholesterintransport bedeutende antiatherogene Eigenschaften auf. Allerdings zeigen 
aktuelle Studien, dass die vaskulären Effekte von HDL sehr heterogen sein können. Ziel des 
Projektes war es, die vasoprotektiven Eigenschaften von HDL von Patienten mit einer 
chronischen Niereninsuffizienz zu untersuchen. 
Im Gegensatz zu HDL von Gesunden (HDLHealthy) führte die Inkubation von humanen aortalen 
Endothelzellen (HAEC) mit HDL von Nierenkranken (HDLCKD) zu einer dramatischen 
Hemmung der endothelialen Stickstoffmonoxid (NO) Produktion. Dieser Effekt war bereits mit 
HDL von Patienten mit nur leichtgradig eingeschränkter Nierenfunktion zu beobachten. Im 
Mausmodell führte eine Injektion von HDLCKD zu einem Blutdruckanstieg, während HDLHealthy 
den Blutdruck reduzierte. Ferner konnten wir zeigen, dass HDLCKD in HAEC die Produktion 
von Superoxid-Radikalen stimuliert. Mittels Massenspektromie konnten wir die Akkumulation 
von symmetrischem Dimethylarginin (SDMA) in HDLCKD aber nicht in HDLHealthy nachweisen. 
Außerdem konnten wir zeigen, dass die Inkorporation von SDMA in den HDL (HDLSDMA) 
Partikel zur Veränderung der endothelialen Eigenschaften von HDL führt. HDLSDMA hemmte 
die endotheliale NO-Produktion und förderte die Produktion von Superoxid-Radikalen. Weiter 
konnten wir nachweisen, dass die Effekte von HDLCKD als auch HDLSDMA durch eine 
Aktivierung des Toll-like Rezeptors-2 (TLR-2) auf der Oberfläche von Endothelzellen 
vermittelt werden. Im Gegensatz zu klassischen TLR-2 Liganden, die via TLR-2 zusammen 
mit den Co-Rezeptoren TLR-1 und TLR-6 die NF-κB abhängige Cytokinproduktion 
stimulieren, konnten wir erstmalig aufzeigen, dass für die TLR-2-abhängige Aktivierung von 
Endothelzellen durch HDLCKD und HDLSDMA diese Co-Rezeptoren nicht notwendig sind. 
HDLCKD und HDLSDMA führen beiden über eine Aktivierung des endothelialen TLR-2 zu einer 
direkten Hemmung der stimulatorischen Akt-abhängigen Phosphorylierung der endothelialen 
NO Synthase (eNOS) sowie via Phosphorylierung von SAPK/JNK zu einer NADPH-Oxidase 
abhängigen Produktion von Superoxid-Radikalen. Schließlich konnten wir nachweisen, dass 
die Reduktion der endothelialen NO-Bioverfügbarkeit durch HDLCKD und HDLSDMA auch zu 
einer Aufhebung der anti-inflammatorischen Eigenschaften von HDL und der positiven 
Eigenschaften des HDL auf die Reparatur von Endothelläsionen führt. 
Zusammenfassend konnten wir erstmals zeigen, dass HDL von Nierenkranken endothelialer 
Dysfunktion sowie einen Anstieg des Blutdrucks induziert. Wir konnten ferner nachweisen, 
Zusammenfassung 
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dass die Akkumulation von SDMA im HDL von Nierenkranken die Umkehr der 
physiologischen Eigenschaften des HDLs hin zu einem gefäßschädigenden Partikel 
induziert. Insgesamt zeigen diese Ergebnisse einen neuen Zusammenhang zwischen 
endothelialer Dysfunktion, arterieller Hypertonie sowie dem angeborenen Immunsystem auf. 
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2 Summary 
Chronic kidney disease (CKD) represents a potent cardiovascular risk factor. Thereby, a 
slightly reduced renal function is already associated with an elevated risk for cardiovascular 
events. Besides its role in the reverse cholesterol transport, high-density lipoprotein (HDL) 
from healthy subjects exerts several important vascular effects. However, recent evidence 
suggests that the vascular properties of HDL can be highly heterogeneous. The aim of the 
present project was to examine the vasoprotective effects of HDL from patients with CKD. 
In contrast to HDL from healthy subjects (HDLHealthy), incubation of human aortic endothelial 
cells (HAEC) with HDL from patients with CKD (HDLCKD) markedly inhibited endothelial nitric 
oxide (NO) production. Interestingly, this effect was already present with HDL from patients 
with incipient CKD. In a mouse model, HDLCKD increased the arterial blood pressure, 
whereas HDLHealthy reduced the arterial blood pressure. Moreover, we could show that 
HDLCKD induced the production of superoxide radicals in HAEC. Using a mass-spectrometry 
approach, we identified the accumulation of symmetric dimethylarginine (SDMA) in HDLCKD, 
but not in HDLHealthy. Moreover, we could demonstrate that incorporation of SDMA into HDL 
(HDLSDMA) inverts the vasoprotective properties of HDL. HDLSDMA inhibited endothelial NO 
production and stimulated superoxide production in HAEC. Subsequently, we could reveal 
that the adverse vascular effects of HDLHealthy as well as HDLSDMA are mediated by Toll-like 
receptor-2 (TLR-2) on the surface of endothelial cells. In contrast to classical TLR-2 ligand, in 
which hetero-dimers of TLR-1/2 or TLR2/6 mediate NF-κB-dependent cytokine secretion, we 
could show for the first time that TLR-2 dependent endothelial activation by HDLCKD or 
HDLSDMA is co-receptor independent. Moreover, we found that activation of endothelial TLR-2 
by HDLCKD or HDLSDMA directly reduces the Akt-dependent stimulatory phosphorylation of 
endothelial NO synthase (eNOS) and stimulates the NADPH-oxidase dependent endothelial 
superoxide production via phosphorylation of SAPK/JNK. Moreover, our results indicate that 
the reduced endothelial NO bioavailability in response to HDLCKD or HDLSDMA suppresses the 
anti-inflammatory properties of HDL as well as the effects of HDL on endothelial repair. 
In summary, we could show for the first time that HDLCKD induces endothelial dysfunction and 
increases arterial blood pressure. Moreover, we identified SDMA in the HDL fraction as the 
culprit transforming HDLCKD from a vasoprotective into a noxious particle. Of note, these 
findings reveal a novel link between endothelial dysfunction, hypertension and innate 
immunity. 
Introduction 
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3 Introduction 
3.1 Atherosclerotic diseases as main cause of death in western populations 
Atherosclerotic disease such as myocardial infarction, stroke and peripheral artery disease 
represent the main cause of death in western populations. In 2008, the prevalence of 
cardiovascular disease in the United States was 36.2 % affecting approximately 80.000.000 
US citizens. Moreover, cardiovascular disease was responsible for almost 6.000.000 hospital 
admissions leading to healthcare costs of $ 286.6 Billion. Although the mortality declined 
during the last years, the prevalence of cardiovascular disease remains high (Roger et al. 
2011), presumably because of an increasing prevalence of classical cardiovascular risk 
factors such as age, male sex, diabetes mellitus, hypertension, smoking and hyperlipidemia 
as identified by the Framingham Heart Study (Kannel et al. 1961).  
3.1.1 Pathogenesis of atherosclerosis 
Atherosclerosis is characterized by atheromatous plaques developing in the inner surface of 
arteries, which can disrupt and then promote the formation of thrombi. Subsequently, these 
thrombi may lead to flow-limiting stenoses of the blood vessels causing tissue ischemia, 
which clinically manifests as myocardial infarction or stroke. The process of atherogenesis is 
depicted below (Figure 1). 
The normal endothelium represents a barrier preventing activation and adhesion of 
circulating vascular cells such as mononuclear cells (MNC), lymphocytes or platelets. Once 
activated by a variety of stimuli (e.g. tumor necrosis factor α [TNF-α], interleukin 1β [IL-1β], 
angiotensin-2, modified low-density lipoprotein [LDL]), endothelial cells express cell adhesion 
molecules (CAM; e.g. intercellular adhesion molecule [ICAM], vascular cell adhesion 
molecule 1 [VCAM-1] or selectins) and secrete proinflammatory cytokines, which promote 
chemotaxis and adhesion of circulating vascular cells to the endothelial monolayer (Weber et 
al. 2008; Hansson et al. 2011). Besides, changes of the endothelial permeability promote the 
accumulation of lipids and lipoproteins in the subendothelial layer (Tabas et al. 2007). 
Subsequently, MNC can transmigrate into the subendothelial layer, where they are activated 
to differentiate into macrophages. There, macrophages engulf lipids and lipoproteins and 
become foam cells. Moreover, vascular smooth muscle cells (VSMC) migrate from the media 
into intima and start to proliferate. They release extracellular matrix constituents such as 
collagen and elastin, which form a fibrous cap covering the plaque. Thereby, the plaque 
consists of macrophage-derived foam cells, extracellular lipid deposits, cholesterol crystals 
and apoptotic cell debris, which can not be efficiently removed leading to the formation of a 
necrotic core of the plaque (Tabas 2010). After physical disruption of the fibrouse cap, 
Introduction 
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extracellular matrix constituents are exposed to blood, which induces the activation of the 
plasmatic coagulation cascade and platelets leading to the formation of thrombi. 
  
  
  
  
Figure 1 – Process of atherogenesis 
 
3.1.2 Endothelial dysfunction – the promoter of atherogenesis in CKD 
The endothelium is the largest organ of the human body consisting of approximately 1013 
cells with a total surface of roughly 1.000 m2. Endothelial cells cover the vasculature as a 
barrier between the blood stream and the vessel wall. However, the endothelium is rather a 
complex control center than a simple physical barrier. Endothelial cells are key regulators of 
the vascular homeostasis: they control vascular tone, modulate inflammation of the vessel 
wall, equilibrate platelet activation and hemostasis, thereby interacting with other cell types of 
the vessel wall (e.g. vascular smooth muscle cells, macrophages) and circulating blood cells 
(e.g. mononuclear cells, platelets) (Fleming et al. 2003; Rao et al. 2007; Munzel et al. 2008). 
To regulate vascular function and structure, endothelial cells produce a broad variety of anti-
Introduction 
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atherosclerotic substances, of which nitric oxide (NO) is the best characterized and most 
studied. Generated by endothelial NO synthase (eNOS), NO induces relaxation of vascular 
smooth muscle cells, prevents expression of vascular cell adhesion molecules and adhesion 
of leukocytes, and inhibits platelet activation (Feletou et al. 2011).  
 
Function Factor / Mediator 
Regulation of vascular 
tone 
! Nitric oxide 
! Cyclooxygenase derived products (e.g. prostacyclin) 
! Endothelial-derived hyperpolarizing factor (EDHF) 
! Endothelial-derived contracting factor (EDCF) 
! Endothelin-1 
! Angiotensin II 
! C-type natriuretic peptide 
! Bradykinin 
Regulation of thrombosis 
and hemostasis 
! Nitric oxide 
! Tissue plasmin activator (tPA) 
! Thrombomodulin 
! Prostaglandin 
! Plasminogen activator inhibitor-1 (PAI-1) 
! Tissue factor (TF) 
! Tissue factor pathway inhibitor (TFPI) 
! Platelet activating factor (PAF) 
! Von Willebrand’s factor (vWF) 
Regulation of vascular 
inflammation 
! Monocyte chemotactic factor-1 (MCP-1) 
! Cell adhesion molecules (VCAM-1, ICAM-1, E-selectin) 
! Interleukin 1, 6, 18 
! Tumor necrosis factor α 
Regulation of cell 
proliferation 
! Nitric oxide 
! Transforming growth factor-β 
! Endothelin-1 
! Angiotensin II 
! Platelet derived growth factor (PDGF) 
! Basic fibroblast growth factor 
! Insulin like growth factor 
Table 1 – Vascular function affected by endothelial cells and selected mediators 
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Deterioration of these beneficial endothelial effects (endothelial dysfunction) is thought to be 
the first critical step in the pathogenesis of atherosclerosis (Ross 1999). 
A widely used definition of endothelial dysfunction refers to a dysbalance between the 
production of vasodilatory and vasoconstrictive substances by the endothelium. However, 
endothelial dysfunction may include deterioration of more endothelial properties than 
dysregulation of the vascular tone. Accordingly, endothelial dysfunction can generally be 
defined as an impairment of endothelial functional properties leading to abnormal endothelial 
activation. 
 
Abnormal endothelial vasomotor function 
The regulation of the vascular tone in cross-talk with vascular smooth muscle cells (VSMC) is 
a key feature of the endothelium. This is achieved by secretion of vasodilatory substances 
such as NO, prostacyclin and endothelial-derived hyperpolarization factor (EDHF), which 
induce relaxation of VSMC. However, in chronic kidney disease (CKD) several substances 
like homocysteine, endogenous methylarginines (e.g. asymmetric and symmetric 
dimethylarginine), or modified lipoproteins inhibit eNOS resulting in a reduced NO 
bioavailability. Moreover, some of them activate endothelial oxidases (e.g. NADPH oxidase, 
xanthine oxidase) to produce reactive oxygen species (ROS), which can directly act on 
vascular smooth muscle cells, react with NO to form the peroxynitrite radical or induce 
uncoupling of eNOS to produce ROS. In addition, cyclooxygenase-derived factors and 
endothelin-1 are released, causing a contraction of the smooth muscle cells together with 
ROS (Forstermann 2008; Shi et al. 2009; Feletou, Kohler et al. 2011; Vanhoutte 2011). 
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Figure 2 - Crosstalk between endothelial cells (EC) and vascular smooth muscle cells (VSCM) in health 
and chronic kidney disease. (A) In healthy subjects, endothelial-derived factors like nitric oxide (NO), 
endothelial-derived hyperpolarizing factor (EDHF) and prostacyclin (PGI2) induce relaxation of vascular 
smooth muscle cells. (B) In chronic kidney disease, several substances inhibit endothelial NO production 
und induce production of reactive oxygen species (ROS) resulting in VSMC contraction. ADMA = 
asymmetric dimethylarginine, SDMA = symmetric dimethylarginine, AGE = advanced glycation 
endproducts, TXA2 = Thromboxan A2, PG = prostaglandins, AngII = angiotensin II, TGFβ = transforming 
growth factor β, TNFα = tumour necrosis factor α. 
 
Abnormal endothelial secretory function 
CKD is characterized by abnormal endothelial activation. Several substances circulating in 
the plasma of patients with impaired kidney function activate the transcription of distinct pro-
inflammatory genes acting on endothelial transcription factors like NF-κB. The release of pro-
coagulatory proteins (e.g. tissue factor) and activation of platelets induce a prothrombotic 
state. Vice versa, activated platelets secrete cytokines (e.g. IL-1β, RANTES), which further 
promote endothelial activation. Activated endothelial cells also produce cytokines, which act 
in an autocrine and paracrine manner by stimulation and chemotaxis of circulating 
leukocytes. Endothelial cell adhesion molecules enable adhesion and transmigration of 
mononuclear cells and T lymphocytes resulting in endothelial inflammation (Endemann et al. 
2004; Rocha et al. 2009). Finally, abnormal endothelial activation leads to progressive 
endothelial apoptosis and damage with shedding of endothelial micro-particles and 
detachment of endothelial cells (Martinez et al. 2005). 
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3.2 Chronic kidney disease and cardiovascular risk 
Chronic kidney disease (CKD) represents a major public health problem. Within the last 
years, the prevalence of CKD in western population steadily increased. Current data indicate 
a prevalence for CKD of approximately 14 % (2012). 
CKD is associated with an enhanced morbidity and mortality due to cardiovascular events. 
The adjusted survival probability in patients with end-stage renal disease (ESRD) 60 months 
after initiation of renal replacement therapy is only 30 % and the risk of ESRD patients to die 
within the first year after initiation of renal replacement therapy is approximately 23 % (2012). 
With 41.6 %, cardiovascular disease represents the major cause of death in patients with 
ESRD. The mortality due to cardiovascular events is 10 to 100 fold increased in patients with 
ESRD as compared to age- and sex-matched control subjects without kidney disease (Foley 
et al. 1998; Go et al. 2004). 
However, also patients in earlier stages of CKD exhibit an extremely elevated risk for 
cardiovascular events (Go, Chertow et al. 2004). Moreover, several studies identified a 
slightly reduced renal function or a microalbuminuria as strong cardiovascular risk factors 
(Foley, Parfrey et al. 1998; Garg et al. 2002; Garg et al. 2002; Arnlov et al. 2005; Shlipak et 
al. 2006; Menon et al. 2007; Van Biesen et al. 2007). Notably, most patients with CKD die 
before reaching ESRD because of cardiovascular events (Foley et al. 2005).  
Traditional cardiovascular risk factors such as hypertension, diabetes, smoking, and 
dyslipidemia are highly prevalent in patients with CKD (Foley et al. 2005). However, CKD 
itself represents a cardiovascular risk and the presence of traditional risk factors alone may 
not be sufficient to explain the high cardiovascular morbidity and mortality in CKD patients 
(Muntner et al. 2005; Shlipak et al. 2005). Traditional and nontraditional cardiovascular risk 
factors in patients with CKD are summarized in the following table: 
 
Traditional risk factors Nontraditional risk factors Dialysis-related risk factors 
! Hypertension 
! Dyslipidemia 
! Diabetes 
! Smoking 
! Age 
! Anemia 
! Calcium-phosphate 
imbalance 
! Proteinuria 
! Inflammation and 
oxidative stress 
! Coagulation 
! Activation of renin-
angiotensin-aldosteron 
system 
! Hyperhomocysteinemia 
! Left ventricular 
hypertrophy 
! Bacteremia 
! Chronic glycemia 
! Extracellular fluid 
overload 
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Table 2 – Traditional and nontraditional cardiovascular risk factors in patients with CKD, adapted from 
(Rucker et al. 2009) 
Moreover, the results from LDL-lowering studies in patients with CKD clearly document the 
presence of a different pathophysiology of cardiovascular disease in CKD patients as 
compared to those with a normal kidney function: While treatment with statins to reduce LDL 
cholesterol has convincingly been demonstrated to reduce cardiovascular risk in patients with 
normal kidney function at a high risk for cardiovascular events, similar studies in ESRD 
patients have not been proven beneficial (Baigent et al. 2011). 
  
3.3 Vascular effects of High-Density Lipoprotein (HDL) 
HDL plays a crucial role in the reverse cholesterol transport i.e. removing cholesterol from 
peripheral tissues. 
 
 
Figure 3 – HDL metabolism and reverse cholesterol transport (RCT). ABCA1, ATP binding cassette 
transporter A-1. ABCG-1, ATP binding cassette transporter G-1. PL, phospholipids. FC, free cholesterol. 
apoA-I, apolipoprotein A-I. VLDL, very low-density lipoprotein. PTLP, phospholipid transfer protein. 
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LCAT, lecithin:cholesterol acyltransferase. CE, cholesterol ester. CETP, cholesterol ester transfer 
protein. TG, triglycerides. LDLR, LDL receptor. SR-BI, scavenger receptor BI. 
 
Mature HDL particles exhibit a complex structure consisting of a lipid and a protein moiety 
(apolipoprotein). Upon secretion by the liver and the intestine, apolipoprotein A-I (apoA-I) is 
immediately lipidated by accepting free cholesterol (FC) and phospholipids (PL) from liver, 
small intestine and peripheral tissues mediated by ATP binding cassette transporter A-1 
(ABCA1). This results in the formation of the discoid nascent HDL. Subsequently, nascent 
HDL acquires further FC and PL from peripheral tissues as well as from hydrolysis of 
triglyceride-rich lipoproteins (e.g. VLDL) mediated by phospholipid transfer protein (PLTP), 
lipoprotein lipase.  
The HDL-associated enzyme lecithin:cholesterol acyltransferase (LCAT) induces the 
esterification of free cholesterol to cholesterol ester (CE) accumulated in the nascent HDL 
particle. The increasing hydrophobicity evokes an accumulation of CE in the core of the HDL 
particle, which gives rise to the typical spherical structure of the mature HDL particle. 
The removal of CE from HDL may occur via direct interactions between HDL and the hepatic 
scavenger receptor BI (SR-BI) or by the exchange from CE in the HDL fraction with 
triglycerides from apoB containing lipoproteins (VLDL, LDL), a process which is mediated by 
the lipid transporter cholesterol ester transfer protein (CETP). ApoB containing lipoproteins 
loaded with CE are then cleared from the circulation by the hepatic LDL receptor (LDLR). 
Beside its role in the reverse cholesterol transport, HDL from healthy subjects exerts several 
potent vasoprotective effects mainly by targeting endothelial cells. HDL increases the 
endothelial NO bioavailability and reduces the production of reactive oxygen species (ROS) 
in endothelial cells. Additionally, HDL prevents endothelial pro-inflammatory and pro-
coagulatory activation. Moreover, HDL reduces apoptosis of endothelial cells and stimulates 
endothelial repair mechanisms. 
3.3.1 HDL and endothelial NO production 
NO plays an important in the regulation of vascular integrity. In vascular endothelial cells, 
HDL from healthy subjects promotes the formation of NO by modulating the activity of 
endothelial NO synthase (eNOS), the endothelial NO producing enzyme. The pathways 
mediating endothelial NO production in response to HDL from healthy subjects are 
summarized in the following figure. 
Introduction 
 18 
 
Figure 4 – Molecular pathways of HDL-mediated NO production in endothelial cells. S1P3, sphingosine-1 
phosphate receptor 3. SR-BI, scavenger receptor BI. 7-KC, 7-ketocholesterol. ABCG1, ATP binding 
cassette transporter G-1. PZDK1, multi PDZ domain-containing adaptor protein 1. PI3K, phosphoinositide 
3-kinase. Akt, protein kinase B (PKB). ERK1/2, extracellular signal-regulated kinases 1/2. ROS, reactive 
oxygen species. eNOS, endothelial NO synthase. P, phosphorylation. 
 
SR-BI was the first receptor on the surface of endothelial cells identified to mediate NO 
production in response to HDL (Yuhanna et al. 2001). Being colocalized with eNOS in 
endothelial caveolae, SR-BI induces the activation of phosphoinositide 3-kinase (PI3K) in 
endothelial cells. Subsequently, PI3K induces the phosphorylation Akt (protein kinase B, 
PKB) at Serine 473 residue, which then phosphorylates eNOS at Serine 1177 residue. Serine 
1177 represents an eNOS-activating phosphorylation site, which has been identified as an 
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important regulatiry site of eNOS enzymatic activity (Dimmeler et al. 1999; Assanasen et al. 
2005). Furthermore, it has been documented that activation of PI3K also induces 
phosphorylation of the mitogen-associated protein kinases (MAPK) extracellular signal-
regulated kinases 1/2 (ERK1/2) in endothelial cells. Similarly, ERK1/2 phosphorylates eNOS 
at Serine 1177 residues and activates eNOS to produce NO (Mineo et al. 2003). 
Moreover, sphingosine-1 phosphate, a major lipid constituent of HDL, also induces 
endothelial NO production via interaction with its sphingosine-1 phosphate receptor 3 (S1P3). 
Thereby, interaction of HDL with the endothelial S1P3 receptor activates eNOS via PI3K-
dependent phosphorylation of Akt at Serine 473 residue and via direct PI-PLC 
(phosphatidylinositol-specific phospholipase C) dependent phosphorylation of eNOS at 
Serine 1177 residue (Nofer et al. 2004; Theilmeier et al. 2006). 
Recently, the ATP binding cassette transporter ABCG-1, which plays an important role in the 
transport of phospholipids and free cholesterol from macrophages to HDL, was identified to 
be also involved in the regulation of HDL-mediated NO production in endothelial cells. ABCG-
1 prevents endothelial dysfunction by preventing uncoupling of eNOS. Moreover, ABCG-1 
mediates the export of 7-ketocholesterol (7-KC) from endothelial cells, which reduces 
endothelial ROS production and stabilizes eNOS conformation in order to maintain its 
enzymatic activity (Terasaka et al. 2008). 
Notably, the relevance of these findings has been proven in hypercholesterolemic patients, in 
whom infusion of reconstituted HDL (rHDL) improved endothelial function in a NO-dependent 
manner as determined by flow-mediated vasodilation (FMD) (Spieker et al. 2002). 
3.3.2 Impact of HDL on other endothelial-protective properties 
Besides its important impact on NO bioavailability, HDL from healthy subjects exerts 
additional beneficial effects on the endothelium promoting vascular integrity. 
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Figure 5 – Effects of HDL from healthy subjects on endothelial procoagulatory and proinflammatory 
activation as well as on endothelial repair. TNFα, tumor necrosis factor α. SDMA, symmetric 
dimethylarginine. AngII, angiotensin II. ET-1, endothelin 1. ROS, reactive oxygen species. TF, tissue 
factor, 5HT, serotinin. vWF, von Willebrand factor. IL-1β, interleukin 1β. RANTES, regulated and normal T 
cell expressed and secreted. MCP-1, monocytes chemotactic protein-1. MMP, matrix metalloprotease. 
CAM, cell adhesion molecule. EC, endothelial cell. EPC, endothelial progenitor cell. MP, microparticle. 
CEC, circulating endothelial cell. 
 
Several substances circulating in blood of patients with CKD such as proinflammatory 
cytokines, uremic toxins, methylarginines, angiotensin II, endothelin-1 and reactive oxygen 
species lead to an abnormal activation of endothelial cells. In response to these stimuli, 
vascular endothelial cells produce a variety of mediators, which convey the endothelium into 
a procoagulatory, proinflammatory and proapoptotic state. 
 
Regulation of endothelial procoagulatory activation 
Abnormally activated endothelial cells secrete several procoagulatory factors, which on one 
hand induce the activation of plasmatic coagulation pathways and on the other and the 
activation of platelets. In contrast to these factors, HDL from healthy subjects exerts 
antithrombotic effects on endothelial cells and platelets. HDL reduces abnormal endothelial 
activation by reducing the expression of tissue factor (TF) and P/E-selectin on endothelial 
cells. In addition, HDL diminishes the generation of thrombin via upregulation of the anti-
coagulatory factors activated protein C (APC), protein S as well as thrombomodulin. 
Moreover, HDL inhibits the activation of platelets by decreasing the secretion of platelet 
activating factor (PAF) and thromboxane A2 (Mineo et al. 2006). 
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Importantly, the antithrombotic activity of HDL is broadly modulated by its effect on 
endothelial NO production. NO is known to preserve blood flow, to reduce endothelial 
activation and to inhibit platelet activation. Thus, NO generation in response to HDL does not 
only affect the vascular tone, but also HDL’s antithrombotic properties. 
 
Regulation of endothelial proinflammatory activation 
The expression of adhesion molecules and the secretion of proinflammatory and chemotactic 
cytokines by the activated endothelium represents a prerequisite for endothelial adhesion 
and transmigration of mononuclear cells into the subendothelial layer and, thereby, for the 
formation atherosclerotic lesions and plaques. It has been previously shown that HDL from 
healthy subjects reduces the expression of vascular cell adhesion molecule 1 (VCAM-1) and 
intercellular adhesion molecule 1 (ICAM-1) on endothelial cells (Cockerill et al. 1995; Patel et 
al. 2010). Moreover, HDL attenuates the expression of CD11b on mononuclear cells and 
consequently reduces their adhesion to activated endothelial cells (Murphy et al. 2008). 
Notably, the anti-inflammatory properties of HDL are at least partially mediated by eNOS and 
the interaction between HDL and SR-BI as well as S1P receptors (Kimura et al. 2006). 
 
Regulation of endothelial apoptosis 
Apoptosis, the programmed cell death of endothelial cells is a crucial part of atherogenesis. 
A broad variety of stimuli (such as TNFα, oxLDL, IL-1β, ROS), circulating in the blood of 
patients with cardiovascular risk factors, may induce endothelial cells to undergo apoptosis 
(Dimmeler et al. 2002). It has been documented that HDL feature an intrinsic anti-apoptotic 
activity. In response to several stimuli, the constituents of HDL, apo-AI as well as spingosine-
1 phosphate reduce endothelial caspase-3 activity, maintain the mitochondrial membrane 
potential and reduce the formation of ROS by the mitochondrial respiratory chain (Suc et al. 
1997; Sugano et al. 2000; Nofer et al. 2001; Kimura et al. 2003).  
 
HDL and endothelial repair 
Several repair mechanisms may counteract the formation of endothelial lesions. Proliferation 
and migration of endothelial cells into de-endothelialized areas play an important role in 
preventing the formation of atherosclerotic lesions (Niimi et al. 1994). Moreover, despite an 
ongoing controversy about their phenotypic and ontogenetic definition, endothelial progenitor 
cells (EPCs) have been documented under several conditions to promote the repair of 
endothelial lesions presumably by paracrine effects (Bahlmann et al. 2010; Fadini et al. 
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2012). Clinical studies documented an associaton between the number of circulating EPCs 
and cardiovascular outcome (Schmidt-Lucke et al. 2005; Werner et al. 2005). 
HDL induces both migration and proliferation of endothelial cells (Tauber et al. 1981; 
Murugesan et al. 1994; Tamagaki et al. 1996). Interestingly, these effects of HDL are also 
mediated via SR-BI and S1P (Seetharam et al. 2006). Moreover, HDL stimulates 
phosphorylation of Akt in human peripheral blood mononuclear cells (PBMC), their 
differentiation into EPCs as well as their migratory and tube formation activity in an SR-BI, 
PI3K and eNOS dependent manner (Tso et al. 2006; Sumi et al. 2007; Feng et al. 2009). In 
vivo, HDL increases capillary density and blood flow recovery in a hindlimb ischemia model. 
Furthermore, re-endothelialized after perivascular carotid injury was reduced in apoA-I-/- mice 
as compared to apoA-I+/+ mice. In these experiments, the effect of HDL on endothelial repair 
was blunted in SR-BI deficient mice (Seetharam, Mineo et al. 2006).  
Taken together these findings clearly indicate that HDL from healthy subjects not only 
protects endothelial integrity but also potently promotes endothelial repair mechanisms. 
 
3.4 Aim of the present project 
Recent evidence suggests the vascular effects of HDL can be heterogeneous. It has been 
demonstrated by our group that HDL can loose its vasoprotective under several disease 
conditions such as coronary artery disease, diabetes and antiphospholipid syndrome 
(Charakida et al. 2009; Sorrentino et al. 2010; Besler et al. 2011). 
These observations led to the following hypothesis: 
 
CKD alters the endothelial-protective properties of HDL and may therefore contribute 
to the high burden of cardiovascular disease in these patients. 
 
Therefore, the aim of the present project was to examine the effect of HDL from CKD 
patients as a group of patients with an extraordinary high cardiovascular risk on distinct 
known endothelial functions of HDL. 
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4 Material and Methods 
4.1 Animals 
Wildtype (WT; C57BL/6J), Tlr2–/– (B6.129-Tlr2tm1Kir/J), Tlr4-/- (B6.B10ScN-Tlr4lps-del/JthJ), 
eNOS–/– (B6.129P2-Nos3tm1Unc/J) mice were obtained from The Jackson Laboratory, Tlr1-/- 
and Tlr6-/- mice from OrientalBioService, and CD1(nu/nu) from Charles River. Mice were 
housed and maintained in the Saarland University Hospital Animal Facility. All animal studies 
were approved by the animal ethics committee of the Saarland University and the University 
of Zurich, respectively.  
 
4.2 ESR spectroscopy analysis of nitric oxide (NO) production in HAEC and 
BAEC 
NO production was measured by ESR spectroscopy analysis with the use of the spin-trap 
colloid Fe(DETC)2 as described previously (Kleschyov et al. 2000; Sorrentino, Besler et al. 
2010). Cells were stimulated with the isolated lipoproteins or Pam3CSK4, respectively, for 1 
hr. 
 
4.3 ESR spectroscopy analysis of superoxide production in HAEC 
Endothelial superoxide was measured using ESR spectroscopy and the spin trap 1-hydroxy-
3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH) as described previously 
(Landmesser et al. 2002; Sorrentino, Besler et al. 2010). Cells were stimulated with the 
isolated lipoproteins or Pam3CSK4, respectively, for 1 hr. 
 
4.4 Blood pressure measurements in mice 
Systolic blood pressures were measured by a computerized tail-cuff system (Visitech 
Systems) as described previously (Landmesser, Cai et al. 2002). On each day of blood 
pressure determination, 20 measurements were obtained and averaged for each mouse. 
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4.5 Bone-marrow transplantation 
Bone-marrow transplantation experiments were performed as described previously (Kania et 
al. 2009). In brief, 6-8 weeks old wildtype (WT) or TLR2-/- mice were lethally irradiated with 2 
x 6.5 Gy using Gammatron (Co-60) system, and reconstituted with 2x107 donor bone-marrow 
cells from WT or TLR2-/- mice, respectively. After reconstitution all mice received prophylactic 
antibiotics in the drinking water and were housed in a specific pathogen-free environment for 
6 weeks.   
 
4.6 Clinical study design and participants 
The clinical studies enrolled adults and children with chronic kidney dysfunction as well as 
respective healthy controls (Tables S1-S2). The studies were conducted with approval of the 
local ethics committees (Ethikkommission der Ärztekammer Saarland, Germany, Ethikvotum 
06/10; Research Ethics Committee, Great Ormond Street Hospital, London, UK) and 
informed consent was obtained from all participants or their legal guardians, respectively. 
 
4.7 Lipoprotein isolation 
Lipoproteins were isolated from fresh, fasting plasma by density gradient ultracentrifugation 
(HDL: density 1.063 to 1.21 g/cm3, LDL: density 1.006-1.063 g/cm3) as described previously 
(Havel et al. 1955; Cavelier et al. 2006; Rohrer et al. 2006). Potassium bromide was used to 
adjust the density. Lipoprotein concentrations used in the present study were based on 
protein content, which was determined by Bradford assay. Purity of each lipoprotein 
preparation was assessed by SDS-PAGE and subsequent Coomassie Blue staining of the 
gel. Lipid-free human plasma Apo-A1 was further purified from delipidated HDL as described 
previously (Brown et al. 1969). 
 
4.8 Preparation of reconstituted HDL (rHDL) 
Reconstituted HDL (rHDL) comprising apoA1, POPC, and cholesterol was prepared as 
described previously in detail by the sodium cholate dialysis method using an apoA-
I/POPC/cholesterol molar ratio of 1:100:10 (Oram 2003). 
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4.9 Culture of endothelial cells 
Human aortic endothelial cells (HAEC) were obtained from Clonetics® and cultured in 
Endothelial Cell Growth Medium-2 (Clonetics®, Lonza, Verviers, Belgium) supplemented with 
10 % Fetal Bovine Serum (FBS, Gibco, Invitrogen, Basel, Switzerland). Bovine aortic 
endothelial cells (BAEC) were cultured as described previously (Ohnsorg et al. 2011). Before 
the experiments, cells were starved in Endothelial Basal Medium (Lonza, Verviers, Belgium) 
with 0.5 % FBS overnight. Cells were used within passage 4 to 6.  
 
4.10 Isolation and culture of murine bone-marrow derived macrophages 
Murine bone-marrow cells were isolated from the femora of WT or TLR-/- animals, by 
flushing with sterile PBS and filtering through 40 µm cell strainers (BD Falcon). Cells were 
grown in RPMI1640 supplemented with 10 % FBS, penicillin/streptomycin, MEM non-
essential amino acids, sodium pyruvate, 2-mercaptoethanol (Gibco, Invitrogen) and 50 ng/ml 
M-CSF (Peprotech) for 6 days. 
 
4.11 Determination of methylarginines using HPLC-ESI-MS/MS 
EDTA-plasma or lipoprotein solution (50 µl) was supplemented with 20 µl internal standards 
solution (460 µmol/L 13C6-Arg and 45 µmol/L D7-ADMA both from Cambridge Isotope 
Laboratories, Andover, USA). To precipitate the proteins 200 µl of mixture 
methanol/acetonitrile / 0.1 M aqueous zinc sulphate (80% + 10% + 10%, v/v/v) (Sigma) was 
added. After centrifugation at 16,000 x g for 10 min at 10°C, the supernatant was collected 
and dried under nitrogen at 25°C. The dried sample was derivatised with 100 µl butanol 
solution containing 3 M HCl (Regis technologies, Socochim Lausanne) at 65 °C for 20 min. 
The derivatised samples were dissolved in 100 µL aqueous 0.2% trifluoroacetic acid (v/v) 
solution. 
For the HPLC separation a Rheos 2000 pump with a degasser Rheos DSO-LC (Flux 
Instruments, Basel, Switzerland) and Betasil Phenyl-Hexyl (Symmetry, 3 μm, 3 × 100 mm) 
(Thermo Fisher Scientific) was used. The flow rate was 300 µL/min with a gradient elution of 
solution A (0.2% aqueous trifluoroacetic acid, v/v) and solution B (acetonitril). The 
percentage of organic modifier (B) was changed linearly as follows: 1 min, 5%; 5 min, 50%; 
2.5 min isocratic, 50%; 2.5 min, 5%. The injection volume was 10 µL  and  the total analysis 
run time was 10 min. 
Mass spectrometric analyses were performed using a Thermo Finnigan TSQ 7000 triple 
quadrupole mass spectrometer equipped with an electrospray ion source (ESI) operating in 
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positive mode. Observed multiple-reaction monitoring (MRM) transitions were: m/z 259 > 228 
for SDMA, m/z 259 > 214 for ADMA, and m/z 266 > 77 for its IS (ADMA-D7). Data collection 
and analysis were done with Thermo Xcalibur software package, revision 1.2. 
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Figure 6 - Representative mass chromatograms obtained for the standard mixture of SDMA, ADMA and 
ADMA-D7. Following transitions were used for quantification: m/z 259 > 227 (SDMA), m/z 259 > 214 
(ADMA) and m/z 266 > 77 (ADMA-D7). The concentrations in this mixture were 4 µmol/L for SDMA, ADMA 
and ADMA-D7, respectively. We obtained the following concentrations: SDMA 3.973 µmol/L, ADMA 3.892 
µmol/L. 
 
 
Figure 7 - ESI-MS/MS product ion spectra pattern obtained for (A) ADMA and (B) SDMA. Specific 
fragments used for quantifications are marked with arrows (ADMA 214 m/z, SDMA 228 m/z). 
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Figure 8 - Representative mass chromatograms obtained from plasma (A) of a healthy subject and (B) a 
patient with kidney dysfunction. 
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4.12 Supplementation of lipoproteins with methylarginines 
HDL or LDL were incubated with the indicated concentrations of SDMA or ADMA overnight at 
4 °C on a shaker. Lipoproteins were used after dialysis against Krebs-Henseleit buffer. 
 
4.13 Endothelial cell migration assay 
In vitro scratch assay was used to assess endothelial cell migration as described previously 
(Liang et al. 2007). HAEC were grown until confluency in 24 well plates in EGM-2 medium 
supplemented with 10 % FCS. For the assay, medium was changed to EBM containing 0.5 
% FCS and 50 μg/ml HDL was added. Two parallel linear scratches were performed with a 
200 μl pipette tip and pictures were taken at 4 different positions by phase contrast 
microscopy immediately after scraping and 24 hours later at the same positions. Newly 
closed distance was calculated by subtracting the width of the scratch after 24 hrs from the 
width at time point 0. Each experiment was performed in triplicates and mean was 
calculated. 
 
4.14 Flow cytometric detection of TLR expression 
TLR expression was assessed by flow-cytometry using appropriate antibodies targeting TLR-
2 (clone: 11G7), TLR-4 (clone: HTA125) (BD Pharmingen and Immunokontact), TLR-1 
(clone: H2G2) and TLR-6 (both from Invivogen). 
 
4.15 Carotid injury model 
Female CD1nu/nu nude mice, aged 7 to 10 weeks, were anaesthetized with isoflurane. 
Carotid artery electric injury was performed as described previously (Carmeliet et al. 1997; 
Sorrentino et al. 2007; Sorrentino, Besler et al. 2010). In brief, the left common carotid artery 
was injured with a bipolar microregulator (ICC50, ERBE-Elektromedizin GmbH, Tuebingen, 
Germany). An electric current of 2 W was applied for 2 seconds to each millimeter of carotid 
artery over a total length of exactly 4 mm with the use of a size marker parallel to the carotid 
artery. 15 mg/kg of HDL were injected in volume of 250 μl 3 hours after carotid injury via tail 
vein injection with a 30-gauge needle. Three days after carotid injury,endothelial regeneration 
was evaluated by staining denuded areas with 50 μl of solution containing 5% Evans blue 
dye via tail vein injection. The re-endothelialized area was calculated as difference between 
the blue-stained area and the injured area by computer-assisted morphometric analysis. This 
model has been shown to allow accurate quantification of reendothelialization (Carmeliet, 
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Moons et al. 1997). HDL from each CKD/healthy subject were injected into 2 nude mice, and 
mean values of re-endothelialized area were used for analysis. 
 
4.16 Endothelial mononuclear cell adhesion assay 
HAECs were seeded in 24 well plates and grown until confluency. After serum withdrawal 
overnight, they were stimulated with TNFα (5 ng/ml, 4 hrs) and HDL (50 μg/ml, 3 hrs). 
Peripheral blood mononuclear cells (PB-MNCs) were separated from peripheral whole blood 
of a healthy human volunteer by Ficoll density gradient centrifugation as described previously 
(Krankel et al. 2008). PB-MNCs were labelled with DiI according to the manufacturer’s 
protocol (VybrantTM Cell- Labeling Solutions, Molecular Probes, Invitrogen). Afterwards, 
1x106/well of the labelled MNC were added to the HAECs. After a 4 hrs incubation period, 
non-adherent PB-MNCs were carefully removed by washing with phosphate buffered saline 
(PBS). The integrity of the endothelial monolayer was confirmed by staining with 4’,6-
diamidino-2-phenylindole (DAPI, Vectashield, Reactolab, Servion, Switzerland). Adherent DiI-
labelled PB-MNCs were counted in 4 randomly selected high-power fields using a fluorescent 
microscope (DM-IRB, Leica) connected to a digital imaging system (Spot-RT; Diagnostic 
Instrument/Visitron Systems). 
 
4.17 Generation of HEK-293 cells expressing hSR-BI 
The hSR-BI cDNA was inserted into pcDNA3 vector and transfected into HEK-293 cells using 
lipofectamin 2000. As control pcDNA3 vector without insert was transfected into HEK-293 
cells. Transfected HEK-293 cells were selected in DMEM containing 10% FBS, 2 mM 
glutamine, G418 400 µg/ml, 50 units/ml penicillin and 50 μg/ml streptomycin. Binding studies 
were performed as described for endothelial cells.  
 
4.18 Endothelial cell binding and cell association assays 
Endothelial binding (i.e. binding to the cell surface) and association (i.e. binding to the cell 
surface and internalization) assays using 125I-HDL were performed as described previously 
(Ohnsorg, Rohrer et al. 2011). Briefly, bovine aortic endothelial cells (BAEC) were incubated 
with 125I-HDL without (total) or with (unspecific) a 40-fold excess of unlabeled HDL as 
competitor for 2 hrs at 4 °C or for 1 hr at 37 °C to quantify binding or cell association, 
respectively. After incubation, the amounts of cell bound radioactivity were determined using 
a Perkin Elmer γ-counter and the protein content was analyzed as described previously 
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(Rohrer, Cavelier et al. 2006). Specific binding/cell association was calculated by subtracting 
the values of nonspecific binding/cell association from those of total binding/cell association. 
All experiments were performed at least in triplicates. 
 
4.19 Western Blot techniques 
Protein expression was determined by Western blot analysis. Cells were lysed in lysis buffer 
containing 50 mmol/l Tris pH 7.5, 150 mmol/l NaCl, 1 mmol/l EDTA, 0.5 % NP-40  
supplemented with protease and phosphatase inhibitors (10 μg/ml Aprotinin, 10 μg/ml 
Leupeptin, 0.1 mM Na3VO4, 1 mM NaF, 1 mM PMSF). Protein concentration was determined 
by the Bradford assay. 30 μg of protein were loaded per lane, resolved by 10 % SDS-PAGE, 
transferred to a PVDF membrane (Millipore, Billerica, MA, USA) by semidry transfer. The 
following antibodies and dilutions were used: Goat anti-human VCAM-1 (R&D systems, 
Abingdon, UK, polyclonal) 1:2,000, Mouse anti-human eNOS (pT495) (BD transduction 
laboratories, clone: 31/eNOS(pT495) 1:1,000, Mouse anti-human eNOS (pS1177) (BD 
transduction laboratories, clone: 19/eNOS/S1177) 1:1,000, Mouse anti-human eNOS/NOS 
Type III (BD transduction laboratories, clone: e/eNOS/NOS Type III) 1:1,000, Rabbit anti-
human Phospho-Akt (Ser473) (Cell signaling, clone: 193H12) 1:2,000, Rabbit anti-human Akt 
(pan) (Cell signaling, clone: 11E7) 1:2,000, Rabbit anti-human Phospho-SAPK/JNK 
(Thr183/Tyr185) (Cell signaling, clone: 81E11) 1:2,000, Rabbit anti-human SAPK/JNK (Cell 
signaling, clone: 56G8) 1:5,000, Mouse-anti human GAPDH (Millipore, clone: 6C5) 1:20,000 
as loading control. 
 
4.20 Fluorescent labeling of HDL using Atto-488 
4 mg of HDL from healthy subjects have been diluted in PBS to achieve a final volume of 300 
µl. Afterwards the HDL solution together with 35 µl sodium bicarbonate buffer (1.0 M, pH 9.5) 
was added to a tube containing 25 µl Atto-488-NHS (AttoTec, Germany) and incubated for 2 
hrs at room temperature. After incubation, Atto-488-labeled HDL was purified using gel 
filtration. 
 
4.21 Determination of the interaction between Atto-488-HDL and endothelial 
cells 
Endothelial cells were transfected with a pZERO plasmid containing a dominant-negative 
form of the human TLR-2 (TLR2-ΔTIR-HA) or TLR-5 gene (TLR5-ΔTIR-HA) containing an 
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HA-tag by using Lipofectamine 2000 (Invitrogen, 2.5 µg DNA, 7.5 µl Lipofectamine in 250 µl 
Opti-MEM medium). Transfection efficiency was assessed by measuring TLR surface 
expression as well as by western blot using an anti-HA antibody (Invivogen). 48 hrs after 
transfection, cells were incubated with Atto-488-labeled HDL for 30 min at 37 °C. After 
several washing steps, cells were immediately analyzed for the presence of Atto-488-HDL 
using flow-cytometry. 
 
4.22 TLR blocking experiments 
To neutralize TLR-1 (clone: H2G2), TLR-2 (clone: B4H2), TLR-4 (clone: W7C11), TLR-6 
(clone: C5C8), cells were incubated with the respective neutralizing antibodies (Invivogen) for 
1 hr before stimulation with HDL or TLR agonists. 
 
4.23 Cell-based TLR-2 activation assay 
HEK293 cells co-transfected with the human TLR-2 and SEAP (secreted embryonic alkaline 
phosphatase) genes were purchased from Invivogen. In these cells, the SEAP gene is 
placed under control of the IFN-β promoter and fused to five NF-κB and AP-1 binding sites. 
Stimulation of TLR-2 activates NF-kB and AP-1, which then induce the production of SEAP. 
Notably, these cells express endogenous level of TLR-1 and TLR-6. Cells were cultured in 
DMEM medium containing 4.5 g/l glucose, 10 % FBS, 50 U/ml penicillin, 50 µg/ml 
streptomycin, 100 µg/ml Normocin (Invivogen) and 2 mM L-glutamine. After overnight 
stimulation of the cells with the respective agents, SEAP in the cell culture medium was 
colorimetrically quantified using QUANTI-Blue detection medium (Invivogen) with a 
platereader at 635 nm. 
 
4.24 ELISA 
To determine the concentrations of the cytokines TNF, IL-1β, IL-6, IL-10 IL-12 p40 in cell 
culture supernatant, commercially available ELISA kits (BD OptEIA for mouse, eBioscience 
and Biolegend for human) were used according to the manufacturer’s instructions. 
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4.25 Intracellular cytokine staining 
Intracellular staining for the production of TNFα and IL-6 was performed as described 
previously (Schmidt et al. 2012). Stimulation was performed at 37 °C for 12 hrs (HAEC) or 6 
hrs (human PBMCs).  
 
4.26 Statistics 
All data are expressed as mean ± SEM. Statistical comparisons were made by one-way 
analysis of variance or the nonparametric Kruskal Wallis test. P-value <0.05 was considered 
statistically significant. Post-hoc Tukey test or Bonferroni adjustment was performed for 
multiple comparisons. All analyses were performed with GraphPad Prism (Version 4.0, 
GraphPad Software, Inc.).  
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5 Results 
5.1 Patient recruitment 
For the isolation of HDL from serum samples, adult and children with different degrees of 
CKD as well as respective healthy control subjects were recruited. The clinical characteristics 
of the respective cohorts are provided in the following tables: 
 
 Healthy 
Controls 
N=15 
CKD-II° 
 
N=15 
CKD-III/IV° 
 
N=15 
CKD-V° 
 
N=15 
P 
Age (years) 60 ± 8 60 ± 11 67  ± 12 64 ± 11 0.153 
BMI (kg/m2) 26.7 ± 2.8 29.1 ± 3.9 30.1 ± 5.5 28.1 ± 5.5 0.177 
Male (%) 55.6 57.9 53.3 66.7 0.902 
Diabetes mellitus (%) - 15.8 26.7 40.0 0.386 
HbA1c (%) 5.8 ± 0.3 5.8 ± 0.6 6.4 ± 1.2 5.4 ± 0.6 0.018 
CAD (%) - 10.5 33.3 46.7 0.012 
Hypertension (%) - 94.7 93.3 93.3 0.000 
MAP (mmHg) 101 ± 7 103 ± 10 96 ± 12 98 ± 13 0.157 
CRP (mg/dl) 1.9 ± 1.6 3.3 ± 2.7 3.6 ± 3.3 6.3 ± 6.1 0.035 
Total cholesterol (mg/dL) 191 ± 11 203 ± 47 185 ± 45 169 ± 57 0.116 
Triglycerides (mg/dL) 122 ± 73 170 ± 143 174 ± 91 156 ± 72 0,646 
LDL cholesterol (mg/dL) 118 ± 28 123 ± 41 107 ± 35 96 ± 27 0.046 
HDL cholesterol (mg/dL) 53 ± 16 49 ± 13 45 ± 9 36 ± 7 0.001 
Creatinine (mg/dl) 0.8 ± 0.1 1.0 ± 0.2 2.3 ± 0.8 8.3 ± 3.9 0.000 
eGFR, MDRD 
(mL/min/1.73 m2) 
102 ± 14 71 ± 14 32 ± 20 7 ± 3 0.000 
Urea (mg/dl) 37 ± 12 44 ± 13 100 ± 31 136 ± 52 0.000 
Current Medication      
ACE Inhibitors (%) - 42.1 20.0 26.7 0.019 
AT1 blocker (%) - 47.4 20.0 20.0 0.023 
Beta Blockers (%) - 68.4 73.3 73.3 0.001 
Ca- Antagonists (%) - 26.3 20.0 20.0 0.386 
Diuretics (%) - 73.7 93.3 60.0 0.000 
Statin therapy (%) - 52.6 80.0 40.0 0.000 
Table 3 - Clinical characteristics of adult patients with CKD and respective healthy control subjects 
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 Healthy 
Controls 
N=10 
CKD-III/IV° 
 
N=13 
CKD-V° 
 
N=9 
P 
Age (years) 13 ± 4 13 ± 2 14 ± 4 0.700 
BMI (kg/m2) 22 22.9 ± 2.8 23.3 ± 4.6 0.460 
Male (%) 48 64 60 0.880 
Diabetes mellitus (%) - - -  
CAD (%) - - -  
Hypertension (%) - 15 11 0.000 
CRP (mg/dl) 0.8  ± 1.4 1.1 ± 1.0 4.3 ± 2.9 0.042 
Total cholesterol (mg/dL) 120 ± 27 143 ± 73 159 ± 81 0.065 
Triglycerides (mg/dL) 70 ± 149 88 ± 44 114 ± 105 0.880 
LDL cholesterol (mg/dL) 50 ± 27 66 ± 35 77 ± 46 0.063 
HDL cholesterol (mg/dL) 73 ± 19 81 ± 39 93 ± 85 0.072 
eGFR (mL/min/1.73 m2) 112 ± 18 23 ± 12 8 ± 13 0.000 
Current Medication     
ACE Inhibitors (%) - 7.7 -  
AT1 blocker (%) - - -  
Beta Blockers (%) - - -  
Ca- Antagonists (%) - 7.7 11.1  
Diuretics (%) - - -  
Statin therapy (%) - - -  
Table 4 - Clinical characteristics of children patients with CKD and respective healthy control subjects 
 
5.2 Effect of HDL from healthy subjects and patients with CKD on endothelial 
NO bioavailability and superoxide production 
At first, the production of NO in HAEC after incubation with HDLHealthy as well as HDLCKD was 
studied by using ESR spectroscopy. PBS treated HAEC were used as control. 
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Figure 9 – Endothelial NO production in HAEC incubated for 60 min with HDL (50 µg/ml) determined by 
ESR spectroscopy (n=15 per group). 
 
HDLHealthy stimulated endothelial NO production, whereas HDLCKD strongly inhibited 
endothelial NO production. Notably, this inhibitory effect on endothelial NO production was 
already present with HDL from patients with incipient CKD. 
 
Since there is a frequent debate on HDL raising pharmaceutical therapies, next, endothelial 
NO production in response to increasing concentrations was quantified. 
 
  
Figure 10 – Endothelial NO production in HAEC incubated for 60 min with increasing concentrations of 
HDL (25 µg/ml, 50 µg/ml, 100 µg/ml) determined by ESR spectroscopy (n=3-5 per group). 
 
While increasing concentrations of HDLHealthy further stimulated endothelial NO production, 
we observed that higher concentrations of HDLCKD led to a significantly stronger inhibition of 
endothelial NO production. Thus, we concluded the effects of HDLHealthy as well as HDLCKD to 
be dose-dependent. 
Since pathological conditions such as diabetes, hypertension and coronary artery disease, 
which are known to affects the functional properties of HDL, are frequently observed in adult 
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patients with CKD, we next analyzed the effect of HDL from children with CKD on endothelial 
NO production. 
 
 
Figure 11 – Endothelial NO production in HAEC incubated for 60 min with HDL (50 µg/ml) from children 
with CKD and respective healthy control subjects (n=9-13 per group). 
 
In this experiment, we observed that HDLCKD from children also significantly reduced 
endothelial NO production. Therefore, we concluded that CKD per se and not concomitant 
diseases are responsible for the observed effects of HDLCKD on endothelial NO 
bioavailability. 
Since HDLCKD substantially reduced endothelial NO bioavailability and since NO is known to 
be an important regulator of vascular tone, we next asked on whether HDLCKD may also have 
an effect on arterial blood pressure in vivo. Therefore, we injected HDLHealthy as well as 
HDLCKD into mice and determined the response on systolic blood pressure. 
 
 
Figure 12 – Δ Systolic blood pressure in (A) wildtype and (B) eNOS-/- mice 90 min after injection of HDL 
(50 mg/kg body weight, n=4-6 per group). 
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Interestingly, in wildtype mice, HDLCKD significantly increased the arterial blood pressure, 
whereas injection of HDLHealthy reduced the arterial blood pressure. To investigate as to 
whether these effects of HDLCKD on arterial blood pressure are mediated by eNOS, we 
repeated these measurements in eNOS-/- mice. In these mice, HDLHealthy lost its ability to 
lower the arterial blood pressure indicating that the effects of HDL on arterial blood pressure 
might be mediated by eNOS. 
To gain insights into the mechanism by which HDLCKD may inhibit endothelial NO production, 
we next measured endothelial superoxide production in response to HDL. The superoxide 
radical is known to rapidly react with NO forming the peroxynitrite radical and, thereby, to 
reduce the NO bioavailability (Pacher et al. 2007). 
 
 
Figure 13 – Basal endothelial superoxide production in HAEC incubated with HDL (50 µg/ml) for 1 hr (n=6 
per group). 
 
Indeed, incubation of HAEC with HDLCKD significantly promoted basal superoxide production, 
while HDLHealthy did not affect production of superoxide radicals in HAEC. 
 
5.3 Effect of methylarginines on the endothelial properties of HDL 
We hypothesized, that endogenous NO inhibitors such as asymmetric dimethylarginine 
(ADMA) or symmetric dimethylarginine (SDMA), which are known to accumulate in the serum 
from patients with CKD, may associate with HDLCKD and alter its vasoprotective properties. 
Therefore, we established a HPLC MS/MS approach to determine the levels of ADMA and 
SDMA in the HDL fraction. 
At first, we confirmed that the concentrations of both ADMA and SDMA are elevated in the 
serum from patients with CKD. 
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Figure 14 – Concentrations of ADMA and SDMA in the serum from patients with CKD and healthy 
subjects determined by HPLC/ESI-MS/MS (n=10 per group). 
 
Next we determined the concentrations of ADMA and SDMA in the HDL fractions from 
patients with CKD as well as healthy control subjects. 
 
 
Figure 15 – Concentrations of ADMA and SDMA in the HDL fraction from patients with CKD and healthy 
subjects determined by HPLC/ESI-MS/MS (n=10 per group). 
 
We could not detect any ADMA in the HDL fractions from healthy subjects and patients with 
CKD. However, we found SDMA to be significantly enriched in HDLCKD but not in HDLHealthy. 
Whereas ADMA is known to inhibit endothelial NO production, the effect of SDMA on 
endothelial NO bioavailability has not been examined. Therefore, we supplemented HDL and 
LDL from healthy subjects with SDMA or ADMA and determined the effect of the modified 
lipoproteins on endothelial NO production. 
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Figure 16 – (A) Effect of SDMA alone (4 µM), healthy HDL (50 µg/ml) or LDL (100 µg/ml) supplemented 
with or without SDMA or ADMA (4 µM equivalent to 0.5 µmol/g lipoprotein) on endothelial NO production 
(n=3-6 per group). (B) Effect of HDLHealthy supplemented with different concentrations of SDMA (0.5 
µmol/g HDL protein) on endothelial NO production (n=3 per group). 
 
We observed that HDLHealthy supplemented with SDMA but not ADMA inhibited endothelial 
NO production. Notably, supplementation of LDL with SDMA or ADMA did not alter the effect 
of LDL on endothelial NO production. Moreover, SDMA alone did also not significantly 
change endothelial NO production. In dose-response experiments, SDMA concentrations, 
comparable to those measured in the HDL fraction of CKD patients, significantly reduced the 
production of NO in endothelial cells. These results indicate that SDMA may associate to 
HDL resulting in an inhibition of endothelial NO production. 
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Figure 17 - Effect of HDL (50 µg/ml, 1 hr) supplemented with SDMA (0.5 µmol/g HDL protein) on 
endothelial superoxide production (n=6 per group). 
 
Furthermore, we measured endothelial superoxide production in response to HDL 
supplemented with SDMA (HDLSDMA). Similarly to HDLCKD, we observed that HDLSDMA 
stimulated basal endothelial superoxide production. 
Furthermore, we supplemented reconstituted HDL (rHDL) consisting of Apo-
A1:POPC:cholesterol in a molar ratio of 1:100:10 with and without SDMA and measured its 
effect on endothelial cell NO production. Supplementation of rHDL with SDMA reduced 
endothelial NO production. Moreover, after supplementation with SDMA, apolipoprotein A1 
(Apo-A1) inhibited endothelial NO production, whereas Apo-A1 without SDMA did not 
significantly affect endothelial NO production. This indicates that SDMA may associate with 
Apo-A1, the major apolipoprotein of HDL. 
 
 
Figure 18 - Effect of rHDL (50 µg/ml) or Apo-A1 (25 µg/ml) supplemented with SDMA (0.5 µmol/g protein) 
on endothelial NO production (n=4-6 per group). 
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HDL from healthy subjects is known to stimulate endothelial NO production by Akt-dependent 
eNOS phosphorylation via activation of endothelial scavenger receptor B-I (SR-BI) or 
sphingosine-1 phosphate receptors (Acton et al. 1996; Nofer, van der Giet et al. 2004). Here, 
we found – in contrast to HDLHealthy - that HDLCKD as well as HDLSDMA significantly reduced 
phosphorylation of Akt (Ser473) leading to a reduced eNOS-activating phosphorylation 
(Ser1177) and a significantly enhanced eNOS-inhibiting phosphorylation (Thr495).  
 
 
Figure 19 – (A) Phosphorylation of Akt at Ser473, eNOS activating phosphorylation at Ser1177 and eNOS 
inhibiting phosphorylation at Thr495 determined by western blot analysis in HAEC incubated with HDL 
(50 µg/ml) for 10 min as indicated (blot as representative of at least 3 independent experiments). (B) 
Quantification of Akt phosphorylation at Ser473 in HAEC incubated with HDL (50 µg/ml) for 10 min 
normalized to total Akt expression (n=3-6). (C) Quantification of eNOS-activating phosphorylation at 
Ser1177 in HAEC incubated with HDL (50 µg/ml) for 10 min normalized to total eNOS expression (n=3-6 
per group). (D) Quantification of eNOS-inhibiting phosphorylation at Thr495 in HAEC incubated with HDL 
(50 µg/ml) for 10 min normalized to total eNOS expression (n=3-6 per group). 
 
Therefore, we hypothesized that such modified HDL changes its affinity to these endothelial 
receptors mediating the protective endothelial effects of HDLHealthy.  
Interestingly, binding of HDLHealthy and HDLSDMA to endothelial cells did not differ significantly. 
However, the interaction of HDLSDMA at 37 °C (i.e. cell association) was significantly lower 
compared to HDLHealthy indicating that SDMA changes the association of HDL with endothelial 
cells.  
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Figure 20 – (A) Effect of SDMA-supplementation on endothelial binding of 125I-HDL (n=6 per group). (B) 
Effect of SDMA-supplementation on endothelial association of 125I-HDL (n=4 per group). 
 
To further examine the binding affinity of HDLSDMA to the HDL receptor SR-BI, we performed 
additional binding studies using HEK293 cells transfected with hSRB-I or with an empty 
vector (control). Here, binding of HDLHealthy and HDLSDMA to HEK cells transfected with hSR-
BI did not differ significantly. We repeated the experiment using rHDL supplemented with and 
without SDMA. Also here, we did not observe a difference in the binding capacity of 
HDLHealthy and HDLSDMA to SR-BI.  
 
 
Figure 21 – (A) Binding of 125I-HDL supplemented with SDMA (0.5 µmol/g lipoprotein) to HEK cells 
untransfected or transfected with human SR-BI (n=7-13 per group). (B) Binding of 125I-rHDL supplemented 
with SDMA (0.5 µmol/g lipoprotein) to HEK cells untransfected or transfected with human SR-BI (n=6-8 
per group). 
Collectively, supplementation of 125I-labeled HDL with SDMA reduced the association, but not 
the specific binding to SR-BI or endothelial cells. 
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5.4 HDL supplemented with SDMA activates endothelial Toll-like receptor 2 
TLR-2 and TLR-4 represent receptors of the innate immune system involved in recognition of 
pathogen-associated lipoproteins (Takeuchi et al. 2010). Both, TLR-2 and TLR-4 are 
expressed on HAECs.  
 
 
Figure 22 - Representative histogram of TLR-2 and TLR-4 surface expression on HAEC determined by 
flow-cytometry. 
 
We measured endothelial NO production in HAECs stimulated with HDLHealthy, HDLCKD or 
HDLSDMA in the presence or absence of specific neutralizing antibodies against TLR-2 and 
TLR-4. We observed that blocking of TLR-2 but not TLR-4 restored the effects of HDLCKD and 
HDLSDMA on endothelial NO production. Importantly, the neutralizing antibodies did not affect 
NO production in the presence of HDLHealthy.  
 
 
Figure 23 - Effect of TLR-2 and TLR-4 inhibition using a blocking antibody (10 µg/ml, each) or an isotype 
control antibody (10 µg/ml) on endothelial NO production after incubation with HDLHealthy, HDLCKD and 
HDLSDMA (0.5 µmol/g SDMA, 50 µg/ml HDL, n=3-5 per group). 
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Consistently, injection of HDLCKD into Tlr2-/- mice, but not in Tlr4-/- mice, failed to increase 
ABP. 
 
 
Figure 24 - Δ ABP in Tlr2-/- and Tlr4-/- mice 90 min after i.v. injection of HDLHealthy and HDLCKD (15 mg/kg 
HDL, n=3-6 per group). 
 
To examine whether TLR-2 on circulating mononuclear cells contributes to the effect of 
HDLCKD on ABP, we analyzed wildtype (WT) and Tlr2-/- bone-marrow chimeric mice, which 
were sublethally irradiated and transplanted with bone-marrow from WT or Tlr2-/- mice. We 
observed an increased ABP in HDLCKD-treated mice with intact TLR-2 expression on vascular 
cells, but lack on bone-marrow derived circulating mononuclear cells. These data suggest, 
that TLR-2 on the endothelium but not on circulating mononuclear cells mediates the adverse 
effects of HDLCKD on ABP.  
 
 
Figure 25 - Δ ABP 90 min after i.v. injection of HDLHealthy and HDLCKD (15 mg/kg HDL) in wildtype, Tlr2-/- 
mice 6 weeks after bone-marrow transplantation from wildtype and Tlr2-/- mice as indicated (n=3 per 
group). 
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Of note, the response of ABP did not differ between WT and Tlr2-/- mice after injection of the 
eNOS inhibitor L-NAME. 
 
 
Figure 26 - Δ ABP in wildtype and Tlr2-/- mice 30 min after i.v. injection of L-NAME (17 mg/kg, n=3-6 per 
group). 
 
To assess the interaction between HDLSDMA and TLR-2, we transfected endothelial cells with 
a plasmid encoding for human TLR-2 without its intracellular TIR-domain (TLR2-ΔTIR-HA) 
and incubated them with fluorescent-labeled HDL. As control, we used a plasmid encoding 
human TLR-5 (TLR2-ΔTIR-HA), which is also expressed on the cell surface (Ramos et al. 
2004). Overexpression of TLR-2 increased the interaction of endothelial cells with HDLSDMA, 
whereas overexpression of TLR-5 did not change the interaction with HDL and endothelial 
cells. 
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Figure 27 – (A) Interaction of Atto-488-labeled HDL (20 µg/ml, 30 min) with endothelial cells transfected 
with a plasmid containing hTLR2-ΔTIR-HA or hTLR5-ΔTIR-HA. Mean fluorescence was recorded using 
flow-cytometry (n=6 per group). (B) Representative histogram of TLR-2 surface expression on HAEC 48 
hrs after transfection with an empty vector (blue) or a TLR2-ΔTIR-HA encoding vector (red) determined 
by flow-cytometry. (C) Representative western blot using an Anti-HA antibody 48 hrs after transfection of 
HAEC with an empty vector (mock), a vector encoding TLR2-ΔTIR-HA or a vector encoding TLR5-ΔTIR-
HA. (D) Representative histograms of HAEC transfected with an empty vector (mock), a vector encoding 
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TLR2-ΔTIR-HA or a vector encoding TLR5-ΔTIR-HA treated for 30 min with 20 µg/ml Atto-488 labeled 
HDLHealthy (blue) or HDLSDMA (red) determined by flow-cytometry. 
 
5.5 Modified HDL does not activate NF-κB dependent TLR-2 signaling 
Next, we asked whether activation of TLR-2 in the absence of HDLCKD or HDLSDMA is 
sufficient to inhibit endothelial NO production. Pam3CSK4 and FSL-1 are synthetic 
lipopeptides, known to bind to TLR-2 (Fujita et al. 2003; Jin et al. 2007). Treatment of HAECs 
with Pam3CSK4 or FSL-1 inhibited endothelial NO production. This effect was completely 
abolished in the presence of anti-TLR-2 neutralizing antibodies. In contrast, the TLR-4 
agonist LPS increased endothelial NO production in a TLR-4 dependent manner.  
 
 
Figure 28 - Endothelial NO production after stimulation (1 hr) with the TLR-1/2 agonist Pam3CSK4 (1 
µg/ml), TLR2/6 agonist FSL-1 (100 ng/ml) and the TLR-4 agonist LPS (1 µg/ml) with or without 
preincubation with blocking antibodies against TLR-2 or TLR-4 (10 µg/ml), (n=3-5 per group). 
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In vivo, a single-dose of Pam3CSK4 was sufficient to significantly increase ABP in WT, but 
not in Tlr2-/- mice. 
 
 
Figure 29 - Δ Systolic ABP in wildtype and Tlr2-/- mice 90 min after i.v. injection of Pam3CSK4 (5 mg/kg, 
n=4 per group). 
 
Recognition of bacterial lipoproteins usually requires formation of heterodimer complexes of 
TLR-2 with TLR-1 or TLR-6, respectively (Alexopoulou et al. 2002; Fujita, Into et al. 2003; 
Sandor et al. 2003). Pam3CSK4 is recognized by the TLR-1/TLR-2 and FSL-1 by the TLR-
2/TLR-6 heterodimer resulting in NF-κB pathway activation and proinflammatory cytokine 
release (Beutler 2004). We used human embryonic kidney (HEK)-Blue TLR-2 reporter cells 
to address if modified HDL activates the NF-κB pathway. Surprisingly, in contrast to 
Pam3CSK4 and FSL-1, both HDLCKD and HDLSDMA failed to activate NF-κB pathway in the 
reporter cells under basal conditions. 
 
 
Figure 30 - TLR-2 activity in HEK cells cotransfected with TLR-2 and SEAP under control of NF-κB and 
AP-1 after stimulation with Pam3CSK4 (1 µg/ml), FSL-1 (100 ng/ml), HDL (50 µg/ml) or SDMA (4 µmol/L) for 
18 hrs (n=4 per group, *** P<0.001 compared to untreated cells). 
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Pam3CSK4 induced release of cytokines in bone-marrow derived macrophages from 
wildtype, but not from Tlr2-/- mice, and in human peripheral blood mononuclear cells (PBMC). 
In contrast, production of these cytokines was not stimulated by HDLCKD and HDLSDMA. 
Notably, neither Pam3CSK4 nor HDL did affect cytokine release in HAEC as determined by 
ELISA or intracellular cytokine staining.  
 
 Untreated Pam3CSK4 HDLHealthy HDLCKD-V° HDLSDMA SDMA 
TNF (pg/ml) 
BM-Mθ (WT) < 4 1030 ± 24 < 4 < 4 < 4 < 4 
BM-Mθ (Tlr2-/-) < 4 < 4 < 4 < 4 < 4 < 4 
PBMC < 4 426 ± 4 < 4 < 4 < 4 < 4 
HAEC < 4 < 4 < 4 < 4 < 4 < 4 
IL-1β (pg/ml) 
BM-Mθ (WT) < 4 107 ± 12 < 4 < 4 < 4 < 4 
BM-Mθ (Tlr2-/-) < 4 < 4 < 4 < 4 < 4 < 4 
PBMC < 4 49 ± 3 < 4 < 4 < 4 < 4 
HAEC < 4 < 4 < 4 < 4 < 4 < 4 
IL-10 (pg/ml) 
BM-Mθ (WT) < 2 289 ± 19 < 2 < 2 < 2 < 2 
BM-Mθ (Tlr2-/-) < 2 < 2 < 2 < 2 < 2 < 2 
PBMC 6 ± 1 229 ± 49 6 ± 1 7 ± 1 6 ± 1 8 ± 1 
HAEC < 2 < 2 < 2 < 2 < 2 < 2 
IL-12 p40 (pg/ml) 
BM-Mθ (WT) < 62 1194 ± 47 < 62 < 62 < 62 < 62 
BM-Mθ (Tlr2-/-) < 62 < 62 < 62 < 62 < 62 < 62 
PBMC < 62 1400 ± 130 < 62 < 62 < 62 < 62 
HAEC < 62 < 62 < 62 < 62 < 62 < 62 
IL-6 (pg/ml) 
BM-Mθ (WT) < 2 137 ± 16 < 2 < 2 < 2 < 2 
BM-Mθ (Tlr2-/-) < 2 < 2 < 2 < 2 < 2 < 2 
PBMC < 2 55 ± 11 7 ± 1 7 ± 1 8 ± 5 7 ± 1 
HAEC 3 ± 1 3 ± 1 4 ± 1 5 ± 1 < 2 3 ± 1 
Table 5 - Production of IL-1β, IL-6, IL-10, TNF, IL-12 (p40) in bone-marrow derived macrophages from 
wildtype (BM-MΦ WT) and Tlr2-/- mice (BM-MΦ Tlr2-/-), human PBMC and HAEC stimulated with 
Pam3CSK4, HDLHealthy, HDLCKD-V°, HDLSDMA and SDMA for 24 hours. 
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Figure 31 – (A) Intracellular cytokine staining for TNFα and IL-6 in HAEC and human PBMC incubated with 
HDLSDMA (50 µg/ml) or Pam3CSK4 (1 µg/ml) for 6 hours determined by flow-cytometry (representative for 
n=3 independent experiments). (B) Mean fluorescence intensity after intracellular cytokine staining for IL-
6 in HAEC and human PBMC (n=3). (C) Mean fluorescence intensity after intracellular cytokine staining 
for TNF-α in HAEC and human PBMC (n=3). 
 
Furthermore, we used neutralizing antibodies against TLR-1, TLR-2, and TLR-6 to block NF-
κB activation in the HEK-Blue TLR-2 reporter cells stimulated with Pam3CSK4 and FSL-1. 
As expected, blocking of either TLR-1 or TLR-6 and TLR-2 almost completely abolished 
Pam3CSK4 or FSL-1 induced NF-κB activation. 
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Figure 32 - TLR-2 activity in HEK cells cotransfected with TLR-2 and SEAP under control of NF-κB and 
AP-1 after preincubation with blocking antibodies targeting TLR-2, TLR-4, TLR-1, TLR-6 or isotype control 
(10 µg/ml) for 1 hr and subsequent stimulation with Pam3CSK4 (1 µg/ml) or FSL-1 (100 ng/ml) for 1 hr (n=4 
per group, ** P<0.01 compared to Pam3CSK4 treated cells, ### P<0.001 and ## P<0.01 compared to FSL-1 
treated cells). 
 
5.6 TLR-1- or TLR-6-co-receptor activation is not required to induce TLR-2 
mediated endothelial dysfunction 
We determined the presence of TLR-1- and TLR-6-co-receptors on HAEC by flow-cytometry. 
Of note, in contrast to human PBMC, HAEC only expressed TLR-2 on their surface, while 
TLR-1 and TLR-6 were not detectable. 
 
 
Figure 33 - (A) Representative histogram of TLR-1 surface expression on HAEC and human PBMC 
determined by flow-cytometry. (B) Representative histogram of TLR-6 surface expression on HAEC and 
human PBMC determined by flow-cytometry. 
 
Next, we addressed whether TLR-1 or TLR-6 blockade can restore NO production in HAEC 
treated with Pam3CSK4 or HDLCKD. In contrast to TLR-2 blockade, addition of anti-TLR-1 
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and/or anti-TLR-6 neutralizing antibodies had no effect on endothelial NO production in the 
presence of Pam3CSK4, HDLCKD or HDLHealthy.  
 
 
Figure 34 - Endothelial NO production after preincubation with TLR-1 and/or TLR-6 neutralizing antibody 
or an isotype control antibody (10 µg/ml, 1 hr) and subsequent stimulation with Pam3CSK4 (1 µg/ml) or 
HDL (50 µg/ml, 1 hr, n=3-6 per group). 
 
Collectively, our data suggest that modified HDL activates TLR-2 inducing a TLR-1- and TLR-
6-co-receptor independent pathway in endothelial cells. Consistently, absence of TLR-1 (Tlr1-
/- mice) and TLR-6 (Tlr6-/- mice) in vivo did not prevent the effect of HDLCKD on ABP. 
 
 
Figure 35 - Δ Systolic ABP in Tlr1-/- and Tlr6-/- mice 90 min after i.v. injection of HDLHealthy and HDLCKD (15 
mg/kg, n=4 per group). 
 
Furthermore, we analyzed endothelial superoxide production in response to Pam3CSK4 and 
FSL-1 in the presence or absence of neutralizing antibodies against TLR-2, TLR-1 or TLR-6. 
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We observed elevated superoxide levels in HAEC treated with Pam3CSK4 and FSL-1. 
Blockade of TLR-2, but not TLR-1 and/or TLR-6, prevented this effect. 
 
 
Figure 36 - Endothelial superoxide production after preincubation with a TLR-1, TLR-2 or TLR-6 
neutralizing antibody or an isotype control (10 µg/ml, 1 hr) and stimulation with Pam3CSK4 or FSL-1 (1 
µg/ml or 100 ng/ml, 1 hr; * P<0.05 compared to Pam3CSK4 treated cells, ## P<0.01 compared FSL-1 
treated cells, n=3-6 per group). 
 
5.7 Activation of endothelial TLR-2 inhibits eNOS activating pathways and 
stimulates NADPH oxidase 
Next, we assessed the molecular mechanisms on how TLR-2 activation affects endothelial 
superoxide and nitric oxide production. At first, we analyzed the effect of the TLR-2 agonist 
Pam3CSK4 on endothelial Akt and eNOS phosphorylation. Comparable to HDLCKD and 
HDLSDMA, Pam3CSK4 reduced Akt phosphorylation at Ser473 and, thereby, induced eNOS-
inhibiting phosphorylation at Thr495.  
 
 
Figure 37 - Phosphorylation of Akt at Ser473, eNOS activating phosphorylation at Ser1177 and eNOS 
inhibiting phosphorylation at Thr495 determined by western blot analysis in HAEC incubated with 
Pam3CSK4 (1 µg/ml) for 10 min (blot as representative of 3 independent experiments). 
 
In addition, it has been shown that TLR-2 activation induces NADPH oxidase to produce 
ROS in monocytes and macrophages (Beaulieu et al. 2011), however, its role in endothelial 
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cells remained unclear. By measuring endothelial superoxide production after preincubation 
with a specific chemical inhibitor of NADPH oxidase (VAS-2870), we demonstrated a pivotal 
role for NADPH oxidase in TLR-2 induced endothelial superoxide production. Using L-NAME, 
an eNOS inhibitor, we ruled out eNOS uncoupling as an immediate source of TLR-2 
mediated superoxide production.  
 
 
Figure 38 - Endothelial superoxide production after preincubation with L-NAME (0.3 mM, 1 hr), a specific 
eNOS inhibitor, or VAS-2870 (10 µM, 1 hr), a specific NAPDH-oxidase inhibitor and subsequent 
stimulation with Pam3CSK4 (1 µg/ml; 1 hr, n=3-6 per group). 
 
Notably, inhibition of NADPH oxidase almost completely prevented the effect of HDLCKD, 
HDLSDMA and Pam3CSK4 on endothelial nitric oxide production.  
 
 
Figure 39 - Endothelial nitric oxide production after stimulation with Pam3CSK4 (1 µg/ml) or HDL (50 
µg/ml) with or without preincubation with VAS-2870 (10 µM, 1 hr, n=3 per group). 
 
TLR-2 activation is known to induce phosphorylation of c-Jun N-terminal kinase (JNK) and 
we have recently shown that activation of JNK in endothelial cells induces endothelial 
superoxide production by increasing NADPH oxidase activity (Cabanski et al. 2008; Osto et 
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al. 2008; Shi et al. 2011). Here, we observed that Pam3CSK4 induces JNK phosphorylation 
in HAEC.  
 
 
Figure 40 – (A) Time-dependent effect of TLR-2 activation with Pam3CSK4 (1 µg/ml) on endothelial 
SAPK/JNK phosphorylation (*** P<0.001 compared to basal, blot as representative of 4 independent 
experiments). (B) Effect of HDLHealthy, HDLCKD and HDLSDMA (50 µg/ml, 15 min) on endothelial SAPK/JNK 
phosphorylation (n=3 per group). 
 
Accordingly, SP600125, a JNK inhibitor, abolished the effect of HDLCKD, HDLSDMA and 
Pam3CSK4 on endothelial superoxide and nitric oxide production. 
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Figure 41 – (A) Endothelial superoxide production after incubation with Pam3CSK4 (1 µg/ml) or HDL (50 
µg/ml) for 1 hr with or without preincubation with SP600125, a SAPK/JNK inhibitor (1 µM, n=3-4 per 
group). (B) Endothelial nitric oxide production after stimulation with Pam3CSK4 (1 µg/ml) or HDL (50 
µg/ml) with or without preincubation with SP600125 (1 µM, 1 hr, n=3 per group). 
 
5.8 HDLCKD and HDLSDMA impair endothelial repair and promote inflammatory 
activation 
We and others have previously demonstrated that reduced NO bioavailability along with 
enhanced superoxide production may also impair other endothelial functions, such as 
endothelial repair after injury and its anti-inflammatory capacity (Kubes et al. 1991; 
Sorrentino, Bahlmann et al. 2007). To elucidate whether modified HDL also affects these 
endothelial properties by inhibiting endothelial NO production, we finally assessed the effect 
of modified HDL on endothelial repair and inflammation. 
In an endothelial wound healing assay, HDLHealthy strongly stimulated endothelial cell 
migration, whereas HDLCKD inhibited endothelial migration.  
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Figure 42 – (A) Endothelial cell migration after incubation with HDL (50 µg/ml, 24 hr) in a scratch assay 
(n=4-8 per group). (B) Representative micrographs of endothelial cell migration in a scratch assay after 
incubation with HDL. 
 
In line with these in vitro observations, HDLCKD and HDLSDMA inhibited endothelial repair in 
vivo in a carotid artery injury model. This was in marked contrast to HDLHealthy, which 
promoted endothelial repair.  
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Figure 43 – (A) Reendothelialized area at day 3 after carotid injury and injection of HDLHealthy, HDLCKD or 
HDLSDMA (15 mg/kg) in nude mice. PBS treated animals serve as control (n=7-13 per group). (B) 
Representative photographs of carotid arteries after Evans Blue staining. 
 
In Tlr2-/- mice, we observed that HDLCKD regained its capacity to promote endothelial repair.  
 
 
Figure 44 - Reendothelialized area at day 3 after carotid injury in Tlr2-/- mice with injection of HDLHealthy, 
HDLCKD or HDLSDMA (15 mg/kg). PBS treated animals serve as control (n=6 per group). 
These findings underscore the important role of TLR-2 to mediate adverse endothelial effects 
of HDLCKD and HDLSDMA. 
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Furthermore, we observed that HDLCKD increased endothelial pro-inflammatory activation as 
determined by a higher amount of adhering mononuclear cells to a TNFα-stimulated 
endothelial monolayer, which was in contrast to HDLHealthy. Accordingly, HDLCKD and HDLSDMA 
increased endothelial VCAM-1 expression, while HDLHealthy significantly reduced VCAM-1 
expression on endothelial cells.  
 
 
Figure 45 – (A) Adhesion of mononuclear cells (MNC) to TNF-α (5 ng/ml) treated endothelial cells after 
incubation with HDLHealthy or HDLCKD (50 µg/ml). MNC are stained with DiI and HAEC with DAPI (n=6 per 
group). (B) Representative micrographs of high-power fields of 6 independent experiments obtained by 
fluorescence microscopy.  
 
Next, we analyzed the effect of NO on TNFα induced VCAM-1 expression in the presence of 
HDL. Inhibition of eNOS through L-NAME reduced the anti-inflammatory effects of HDLHealthy 
by enhancing endothelial VCAM-1 expression, whereas supplementation of NO using a solid 
NO-donor, diethylenetriamine/nitric oxide (DetaNO), restored the anti-inflammatory function 
of the endothelium by reducing endothelial VCAM-1 expression.  
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Figure 46 - Effect of HDLHealthy, HDLCKD or HDLSDMA (50µg/ml) with or without co-incubation with L-NAME 
(0.3 mM) and HDLCKD or HDLSDMA with or without co-incubation with DetaNO (1 mM) on TNFα-induced (5 
ng/ml) endothelial VCAM-1 expression (n=3-6 per group). 
 
Taken together, these results clearly suggest that a reduced endothelial NO bioavailability 
induced by HDLCKD and HDLSDMA represents a major mechanism explaining adverse 
endothelial effects of modified HDL.  
Discussion 
 62 
6 Discussion 
The results of the present project demonstrate for the first time that HDL from children and 
adult patients with CKD substantially inhibits endothelial NO production and thereby 
increases ABP. We have identified accumulation of SDMA in HDL from subjects with even 
mild CKD as the culprit converting HDL into a noxious particle. Furthermore, we have shown 
that this abnormal HDL activates endothelial TLR-2 via a novel TLR-1- and TLR-6-co-
receptor independent alternative pathway impairing endothelial repair and enhancing 
endothelial pro-inflammatory activation. 
6.1 Effects of HDLCKD on endothelial NO production 
We describe the effects of HDL from patients with CKD as a population with a particularly 
high cardiovascular morbidity and mortality (Go, Chertow et al. 2004; Van Biesen, De 
Bacquer et al. 2007).  
In healthy individuals, endothelial NO production stimulated by HDL serves as an important 
stimulus to preserve endothelial function (Yuhanna, Zhu et al. 2001; Spieker, Sudano et al. 
2002; Bisoendial et al. 2003; Landmesser et al. 2004; Nofer, van der Giet et al. 2004). It has 
been demonstrated that HDL from healthy subjects induces endothelial NO production via 
interaction with the receptors SR-BI, S1P3 as well ABCG-1 (Yuhanna, Zhu et al. 2001; Nofer, 
van der Giet et al. 2004; Terasaka, Yu et al. 2008). Moreover, infusion of rHDL has been 
described to restore endothelial function i.e. forearm blood flow during intrarterial infusion of 
acetylcholine in vivo in hypercholesterinemic men (Spieker, Sudano et al. 2002). In addition, 
it has been demonstrated that HDL as well as sphingosine-1-phosphate (S1P) reduced 
myocardial injury in an in vivo model of myocardial ischemia/reperfusion in mice (Theilmeier, 
Schmidt et al. 2006). The authors could show that the beneficial effects of HDL in this model 
are mediated by eNOS.  
However, recent evidence suggests that several pathological conditions such as coronary 
artery disease, diabetes or antiphospholipid syndrome may led to a loss of HDL’s stimulatory 
effect on endothelial nitric oxide synthase (Charakida, Besler et al. 2009; Sorrentino, Besler 
et al. 2010; Besler, Heinrich et al. 2011). The authors claimed oxidative modifications of Apo-
A1 as the underlying mechanism for the altered effect of HDL from these patients on 
endothelial NO production.  
By contrast, in the present study, we found that HDL from patients with CKD almost 
completely suppressed endothelial NO production in a dose-dependent manner. Importantly, 
this adverse effect of HDLCKD was already present with HDL from patients with an early stage 
of CKD. These results may contribute to the high cardiovascular risk, which is already 
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present in patients with a slightly reduced renal function (Go, Chertow et al. 2004; Van 
Biesen, De Bacquer et al. 2007). 
To evaluate as to whether CKD and not concomitant disease, which is commonly found in 
adult patients with CKD, we subsequently analyzed the effect of HDL from children with CKD 
on endothelial NO production. Children with CKD already exhibit an increased risk for 
cardiovascular events (Kavey et al. 2006; Shroff et al. 2009; Shroff et al. 2011). However, in 
contrast to adult patients, CKD in children is mainly caused by hereditary kidney disorders or 
glomerulonephritis and not by diabetes or hypertension, which represent the main causes for 
CKD in adults. Notably, HDL from children with CKD also inhibited endothelial NO production 
indicating that the CKD itself and not concomitant diseases is responsible for the observed 
adverse effects of HDL.  
eNOS, the NO generating enzyme in endothelial cells is crucially involved in the regulation of 
vascular tone. Studies in knock-out mice have clearly documented that genetic defiency of 
the eNOS gene leads to an increased blood pressure and promotes the formation of 
atherosclerotic lesions (Huang et al. 1995; Shesely et al. 1996; Chen et al. 2001; Kuhlencordt 
et al. 2001). Moreover, it has been shown that endothelial activation of the S1P3 receptor by 
HDL reduces the arterial blood pressure in rodents (Nofer, van der Giet et al. 2004). To 
evaluate the effect of HDL from CKD patients on arterial blood pressure, we injected HDL 
from healthy subjects or patients with CKD into mice and measured ABP. Indeed, we 
observed that infusion of HDLCKD into mice significantly increased ABP. This observation is of 
overriding importance, since hypertension is a strong promoter of cardiovascular disease and 
frequently observed in patients with CKD (Peterson et al. 1995). Thereby, hypertension does 
not only present a risk factor for cardiovascular disease in CKD patients, but also a risk factor 
for the progression of CKD itself (Peterson, Adler et al. 1995; Jafar et al. 2003; Kunz et al. 
2008). Thus, our results indicate that HDL may be involved into a vicious circle of 
hypertension and CKD.  
Next, we aimed to assess the underlying mechanism responsible for the reduction of 
endothelial NO bioavailability by HDLCKD. Therefore, we quantified endothelial production of 
ROS in response to HDL. ROS are known to be directly involved in the pathogenesis of 
atherosclerotic diseases (Cai et al. 2000; Griendling et al. 2000; Harrison et al. 2003; 
Forstermann et al. 2006). Moreover, ROS can react with NO forming peroxynitrite and 
thereby reduce endothelial NO bioavailability (Pacher, Beckman et al. 2007). Indeed, HDL 
from patients with CKD potently induced endothelial superoxide production, while HDL from 
healthy subjects had no affect on endothelial superoxide production. 
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In contrast to previous reports describing “dysfunctional HDL”, we could demonstrate that 
HDLCKD not only loses its vaso-protective properties but rather changes into a noxious 
particle strongly promoting endothelial dysfunction and hypertension. 
 
6.2 SDMA accumulates in the HDL particle and alters its endothelial effects 
We hypothesized that methylarginines, which accumulate when renal function deteriorates, 
may associate with the HDL particle from CKD patients and affect its vasoprotective 
properties. 
ADMA, a methylation product of L-arginine residues, is an endogenous eNOS inhibitor 
increased in patients with CKD (Boger et al. 1998; Zoccali et al. 2001; Kielstein et al. 2002; 
Fliser et al. 2005). Moreover, it has been demonstrated that infusion of ADMA into healthy 
subjects increases arterial blood pressure, reduces renal plasma flow and cerebral blood 
flow (Kielstein et al. 2004; Kielstein et al. 2006). However, by using a newly modified mass 
spectrometry approach, we ruled out the presence of ADMA in the HDL fraction.  
Surprisingly, we detected substantial amounts of SDMA, an isomer of ADMA, in HDLCKD but 
not in HDLHealthy. We and others have previously demonstrated that SDMA serum 
concentrations are elevated in several clinical conditions such as CKD and pulmonary arterial 
hypertension (Kielstein, Boger et al. 2002; Pullamsetti et al. 2005; Schepers et al. 2011). 
Although SDMA is thought to be functionally inactive, several studies highlighted its 
predictive value for cardiovascular events (Bode-Boger et al. 2006; Meinitzer et al. 2011). 
However, recent trials have indicated a functional role of SDMA in CKD-associated 
cardiovascular disease. Incubation of endothelial cells with SDMA for 24 hours slightly 
reduced endothelial NO production and increased endothelial ROS production (Bode-Boger, 
Scalera et al. 2006). Moreover, it has been shown that SDMA may induce production of ROS 
and proinflammatory cytokines in mononuclear cells (Schepers et al. 2009; Schepers, 
Barreto et al. 2011).  
In order to examine as to whether incorporation of SDMA into the HDL particle may alter the 
ability of HDL to enhance the endothelial NO bioavailability, we supplemented HDL from 
healthy subjects with SDMA and measured NO production. Importantly, supplementation of 
HDL with SDMA in concentrations as measured in patients with CKD resulted in deleterious 
effects of HDLSDMA on endothelial NO production.  
The enzymatic activity of eNOS is tightly regulated by Akt-dependent phosphorylation of 
distinct amino acid residues in the eNOS molecule. While phosphorylation at Serine 1177 
stimulates eNOS enzymatic activity, phosphorylation at Threonine 495 leads to an inhibition 
of eNOS activity. HDL has been shown to promote eNOS-dependent NO production by 
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stimulating phosphorylation of eNOS (Yuhanna, Zhu et al. 2001; Mineo, Yuhanna et al. 2003; 
Drew et al. 2004; Nofer, van der Giet et al. 2004; Assanasen, Mineo et al. 2005; Terasaka, 
Yu et al. 2008). 
We therefore studied the effect of HDLCKD as well HDLSDMA on Akt-dependent eNOS 
phosphorylation in endothelial cells. In line with previous reports, we could document that 
HDLHealthy stimulated Akt-dependent phosphorylation of eNOS at Serine 1177 residue. In 
contrast, HDLCKD as well as HDLSDMA, both, reduced phosphorylation of Akt at Serine 473 
and enhanced phosphorylation of eNOS at Threonine 495 residue. These results indicate 
that HDL from patients with CKD and HDL supplemented with SDMA reduce eNOS 
enzymatic activity by modulating the regulatory phosphorylation of eNOS.  
 
6.3 SDMA associates with apolipoprotein A-I in the HDL particle 
Since supplementation of LDL with SDMA did not change its effect on endothelial NO 
production, we hypothesized that SDMA may be associated to the protein part of the HDL 
complex. Indeed, we observed that rHDL and Apo-A1 supplemented with SDMA reduced 
endothelial NO production, which indicates that SDMA may associate to Apo-A1. These 
findings indicate that the presence of SDMA in the HDL particle may represent a novel 
mechanism leading to deterioration of HDL’s vascular effects and its transformation into a 
pro-atherogenic particle. 
 
6.4 Abnormal HDL interacts with TLR-2 
HDLHealthy exerts its endothelial-atheroprotective effects by binding to the endothelial 
scavanger receptor SR-BI or S1P3 receptors as well as by activating ABCG-1 (Acton, Rigotti 
et al. 1996; Yuhanna, Zhu et al. 2001; Nofer, van der Giet et al. 2004; Assanasen, Mineo et 
al. 2005; Terasaka, Yu et al. 2008). Our data indicate that supplementation with SDMA does 
not change the affinity of HDL to the receptor SR-BI. Therefore, we focused on receptors, 
which are associated with abnormal endothelial activation. TLR-2 and TLR-4 are both 
expressed on endothelial cells (Edfeldt et al. 2002; Grote et al. 2010) and known to be 
activated by microbial lipoprotein patterns (Takeuchi and Akira 2010). Indeed, activation of 
TLR1/TLR-2, TLR-2/TLR-6 or TLR-4 by microbial lipoproteins initiates defense mechanisms 
of the innate immunity against infectious pathogens (Brightbill et al. 1999; Roux et al. 2011). 
Interestingly, it has been shown that TLR-2 may also play an important role in development 
of atherosclerosis (Mullick et al. 2005; Favre et al. 2007; Mullick et al. 2008). Notably, in the 
present study, the selective inhibition or genetic deficiency of TLR-2, but not TLR-4, almost 
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completely abrogated the adverse effects of modified HDL on endothelial NO bioavailability, 
endothelial repair and ABP. Recent evidence suggests, that circulating cells of the lymphoid 
and myeloid compartment are crucially involved in the pathogenesis of hypertension 
(Harrison et al. 2011). Blood pressure measurements using WT and Tlr2-/- bone marrow 
chimeras suggest that TLR-2 expression on endothelial cells, rather than circulating 
mononuclear cells, mediates the adverse effect of HDLCKD on ABP. This suggests that the 
presence of SDMA transforms HDL towards a phenotype that activates this innate immune 
receptor on the endothelium.  
 
6.5 Activation of endothelial TLR-2 induces endothelial dysfunction 
To further understand the functional implications of endothelial TLR-2 activation, we studied 
the effects of TLR2 on distinct endothelial cell functions. We showed for the first time, that 
activation of TLR-2 by its agonists Pam3CSK4 and FSL-1 reduces endothelial NO release 
and that injection of Pam3CSK4 into mice induces an increase of ABP in a TLR-2-dependent 
manner. 
 
6.6 Abnormal HDL induces a novel NF-κB independent pathway of TLR-2 in 
endothelial cells 
It is well known that activation of TLR-1/TLR-2 and TLR-2/TLR-6 by their classical bacterial 
ligands induces the NF-κB-dependent production of cytokines and other proinflammatory 
molecules in a variety of cell types (Alexopoulou, Thomas et al. 2002; Fujita, Into et al. 2003; 
Sandor, Latz et al. 2003; Beutler 2004).  
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Figure 47 – Classical signaling of TLR-2 in mononuclear cells. 
 
Surprisingly, we observed that abnormal HDL did not induce TLR-1/TLR-2 or TLR-2/TLR-6-
mediated NF-κB activation and subsequent cytokine release in endothelial cells or PBMC. 
Notably, blockade of TLR-1 and/or TLR-6 did not affect endothelial NO production and 
superoxide production in response to classical TLR-2 ligands or HDLCKD and HDLSDMA. Thus, 
we were able to document that the effect of TLR-2 activation on endothelial NO production is 
NF-κB independent. In fact, HAEC lack TLR-1 and TLR-6 on the cell surface and therefore 
do not classically respond to bacterial antigens. 
To determine the molecular mechanisms on how endothelial TLR-2 activation may inhibit 
endothelial nitric oxide production, we could document that TLR-2 activation by its ligand 
Pam3CSK4 - similar to HDLCKD and HDLSDMA – did not stimulate Akt-dependent eNOS-
stimulating phosphorylation, but and enhanced eNOS-inhibiting phosphorylation. It has 
recently been shown that TLR-2 activation can induce ROS production in monocytes and 
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macrophages (West et al. 2010; Beaulieu, Lin et al. 2011; West et al. 2011). In the present 
study, we could demonstrate that endothelial activation of TLR-2 induces endothelial ROS 
production. Of note, TLR-2-induced ROS production was abolished after TLR-2 and not TLR-
1 or TLR-6 blockade. This indicates that TLR-2 stimulates endothelial ROS production 
thereby inhibiting NO bioavailability via a novel TLR-1- and TLR-6-co-receptor independent 
alternative pathway. Furthermore, we demonstrate that the TLR-2 induced NF-κB-dependent 
cytokine release and the TLR-2 induced ROS production are two distinct pathways, which 
can be independently targeted by TLR-2 activating agents. In addition, we showed that TLR-
2 induced endothelial ROS production is inhibited by blocking NADPH oxidase, identifying 
NADPH oxidase as prevailing source of ROS after TLR-2 activation via SAPK/JNK, which 
has been previously shown to stimulate vascular superoxide production in vitro and in vivo 
(Osto, Matter et al. 2008; Shi, Cosentino et al. 2011).  
 
6.7 Effects of HDLCKD as well as HDLSDMA on endothelial repair and 
inflammation 
Additionally, we assessed the effect of HDL from CKD patients on endothelial repair and 
inflammation. We could newly document that HDLCKD loses its ability to promote endothelial 
migration and, in vivo, the repair of endothelial lesions in the perivascular carotid injury 
model. Moreover, HDLCKD as well as HDLSDMA, both, did neither suppress TNF-α stimulated 
endothelial VCAM-1 expression nor adhesion of mononuclear cells to a TNF-α activated 
endothelial monolayer. In contrast, HDLHealthy reduced endothelial proinflammatory activation 
by reducing endothelial VCAM-1 expression and, subsequently, endothelial mononuclear cell 
adhesion. Notably, both processes, endothelial repair as well as endothelial proinflammatory 
activation have been previously shown to dependent on endothelial NO bioavailability 
(Kubes, Suzuki et al. 1991; Pacher, Beckman et al. 2007; Sorrentino, Bahlmann et al. 2007). 
These results underscore the impact of an inhibition of the endothelial NO production on 
distinct endothelial properties of HDL. 
 
6.8 Implications for HDL-targeting therapies 
Currently, HDL-targeting therapies are in the focus of clinical cardiovascular research. 
Notably, raising HDL-cholesterol (HDL-C) serum levels in non-CKD patients by using Niacin 
in addition to Statin treatment has not significantly reduced the percentage of patients 
reaching the primary cardiovascular endpoint6.  
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Inhibition of CETP has been recognized as a potent approach to elevate HDL-C serum 
levels. Treating patients with the CETP inhibitor Torcetrapib increased HDL-C serum levels 
by 72.1 % after 12 months of treatment4. Surprisingly, Torcetrapib treatment significantly 
augmented the systolic blood pressure leading to higher rate of cardiovascular events in 
these patients. This effect of Torcetrapib has been mainly attributed to an off-target effect of 
Torcetrapib to increase aldosterone secretion. Therefore, other CETP inhibitors without off-
target effects such as Dalcetrapib have been evaluated. Although Dalcetrapib reliably 
increased HDL-C levels, the investigators of the DAL-HEART program could not document 
any significant reduction of the incidence of the primary endpoint as compared to placebo 
treated subjects37. Moreover, Dalcetrapib treatment did not improve the flow-mediated 
vasodilation as a surrogate for the endothelial NO bioavailability26. These results clearly 
indicate that simple raising of HDL-C serum levels does not automatically entail an 
amelioration or restoration of HDL’s atheroprotective properties. Although these 
aforementioned studies have not been performed in patients with CKD, it remains more than 
questionable as to whether an HDL-increasing therapy would be beneficial in CKD patients. 
In particular, if fundamental changes of the composition and function of HDL are present, as 
intriguingly documented for HDL of CKD patients. 
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7 Conclusion 
Taken together the present study provides several important novel insights. First, we showed 
that even mild CKD inverts HDL’s endothelial-protective properties. In fact, HDLCKD induces 
endothelial dysfunction, impairs endothelial repair and increases ABP. Second, we identified 
SDMA in HDLCKD as the culprit that modifies HDL to induce these deleterious endothelial 
effects. Moreover, we demonstrate that such modified HDL activates endothelial TLR-2 
signaling resulting in enhanced ROS production and inhibition of endothelial NO 
bioavailability. Third, our data provide evidence that these effects are mediated by activation 
of TLR-2 via a novel TLR-1- or TLR-6-co-receptor-independent alternative pathway. These 
data illustrate as to how a small compound like SDMA can modify the HDL particle mimicking 
a damage-associated molecular pattern to activate TLR-2, thereby linking innate immunity, 
endothelial dysfunction and arterial hypertension. These observations may also have 
important clinical implications for HDL-raising therapies in patients with CKD, which have not 
yet proven to be beneficial so far. 
The findings of the present study are summarized in the following figure: 
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Figure 48 – Graphical summary of the results 
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